US20180193305A1 - Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis - Google Patents

Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis Download PDF

Info

Publication number
US20180193305A1
US20180193305A1 US15/887,825 US201815887825A US2018193305A1 US 20180193305 A1 US20180193305 A1 US 20180193305A1 US 201815887825 A US201815887825 A US 201815887825A US 2018193305 A1 US2018193305 A1 US 2018193305A1
Authority
US
United States
Prior art keywords
certain embodiments
mosm
cromolyn
subject
nebulizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/887,825
Other languages
English (en)
Inventor
William Gerhart
Ahmet Tutuncu
Pravin Soni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Respivant Sciences GmbH
Original Assignee
Patara Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patara Pharma LLC filed Critical Patara Pharma LLC
Priority to US15/887,825 priority Critical patent/US20180193305A1/en
Assigned to Patara Pharma, LLC reassignment Patara Pharma, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GERHART, WILLIAM, SONI, PRAVIN, TUTUNCU, AHMET
Publication of US20180193305A1 publication Critical patent/US20180193305A1/en
Assigned to RESPIVANT SCIENCES LTD. reassignment RESPIVANT SCIENCES LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Patara Pharma, LLC
Assigned to RESPIVANT SCIENCES GMBH reassignment RESPIVANT SCIENCES GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: RESPIVANT SCIENCES LTD.
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics

Definitions

  • compositions comprising cromolyn for the treatment of chronic cough due to idiopathic pulmonary fibrosis.
  • compositions and methods for the treatment of chronic cough due to IPF provide compositions and methods for the treatment of chronic cough due to IPF.
  • Subjects treated with the compositions and formulations provided in the disclosure demonstrate a statistically significant and medically relevant improvement in objective cough rates after 14 days of treatment compared to those subjects who received a placebo. These subjects had refractory chronic cough associated with IPF and are unable to find relief with the currently-available treatments (not including the compositions or methods disclosed herein).
  • the disclosure provides a method of treating chronic cough in a subject having idiopathic pulmonary fibrosis (IPF) comprising administering to the subject a pharmaceutical composition comprising from about 1% by weight to about 10% by weight of cromolyn sodium and an ionic osmotic agent with a nebulizer.
  • the pharmaceutical composition comprises about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% by weight of cromolyn sodium.
  • the pharmaceutical composition comprises about 2% by weight of cromolyn sodium.
  • the pharmaceutical composition comprises about 4% by weight of cromolyn sodium.
  • the pharmaceutical composition comprises about 6% by weight of cromolyn sodium.
  • the disclosure provides a pharmaceutically acceptable aerosol for the treatment of chronic cough in a subject having idiopathic pulmonary fibrosis (IPF), comprising droplets of an aqueous solution comprising (i) from about 2% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent comprising (a) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (b) optionally salts of ethylenediaminetetraacetic acid (EDTA), wherein said aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, and wherein said treatment of said chronic cough in said subject is achieved via delivery of a therapeutically effective amount of cromolyn sodium to the lungs of the subject by said subject orally inhaling said pharmaceutically acceptable aerosol.
  • IPF idiopathic pulmonary fibrosis
  • the disclosure provides a pharmaceutically acceptable aerosol for the treatment of chronic cough in a subject having idiopathic pulmonary fibrosis (IPF), consisting of droplets of an aqueous solution consisting of (i) from about 2% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent consisting of (a) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (b) optionally salts of ethylenediaminetetraacetic acid (EDTA), wherein said aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, and wherein said treatment of said chronic cough in said subject is achieved via delivery of a therapeutically effective amount of cromolyn sodium to the lungs of the subject by said subject orally inhaling said pharmaceutically acceptable aerosol.
  • IPF idiopathic pulmonary fibrosis
  • the disclosure provides a pharmaceutically acceptable solution, comprising from about 1% to about 10% by weight of cromolyn sodium and an osmotic agent, wherein an aerosol created from the pharmaceutically acceptable solution is suitable for inhalation by a subject having chronic cough due to idiopathic pulmonary fibrosis.
  • the aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%.
  • the aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30% and a respirable fraction ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 75%.
  • the disclosure provides a dosage form for the treatment of chronic cough in a subject having idiopathic pulmonary fibrosis (IPF) comprising:
  • composition composition, solution, and formulation are used interchangeably throughout the disclosure.
  • the ionic osmotic agent may comprise or consist of an ionic osmotic agent. In certain embodiments of the compositions and formulations of the disclosure, the ionic osmotic agent may comprise or consist of sodium chloride.
  • the ionic osmotic agent of the compositions of the disclosure may comprise between 0.1% and 0.7%, by weight, of the composition, inclusive of the endpoints. In certain embodiments, the compositions of the disclosure may comprise between 0.1% and 0.2%, by weight of the composition, of the ionic osmotic agent inclusive of the endpoints. In certain embodiments, the compositions of the disclosure may comprise 0.2%, by weight, of the composition, of the ionic osmotic agent.
  • compositions and formulations of the disclosure may further comprise a chelating agent.
  • the chelating agent may comprise about 0.01%, or about 0.02%, or about 0.03%, or about 0.04%, or about 0.05%, or about 0.06%, or about 0.07%, or about 0.08%, or about 0.09%, or about 0.1%, or about 0.2%, or about 0.3%, or about 0.4%, or about 0.5%, or about 0.6%, or about 0.7%, or about 0.8% or about 0.9%, or about 1% by weight, of the composition.
  • the chelating agent comprises ethylenediaminetetraacetic acid (EDTA), sodium-EDTA, or sodium citrate.
  • the chelating agent comprises EDTA.
  • the chelating agent comprises sodium-EDTA.
  • the chelating agent comprises sodium citrate.
  • compositions and formulations of the disclosure may further comprise a non-ionic osmotic agent, preferably, wherein the non-ionic osmotic agent comprises or consists of mannitol.
  • compositions and formulations of the disclosure may exclude, or, may not comprise a non-ionic osmotic agent.
  • compositions of the disclosure may not comprise a non-ionic osmotic agent comprising or consisting of mannitol, a sugar alcohol and/or propylene glycol.
  • compositions of the disclosure do not comprise propylene glycol, regardless of any potential functional role of the propylene glycol.
  • compositions and formulations of the disclosure may exclude, or, may not comprise a non-ionic osmotic agent.
  • compositions of the disclosure may not comprise a non-ionic osmotic agent comprising or consisting of mannitol, any other sugar alcohol and/or propylene glycol.
  • compositions of the disclosure do not comprise mannitol, any other sugar alcohol and/or propylene glycol, regardless of any potential functional role, chemical property or use of mannitol, any other sugar alcohol and/or propylene glycol known to those of ordinary skill in the art.
  • compositions and formulations of the disclosure may have a surface tension effective for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli.
  • the compositions and formulations of the disclosure may have a surface tension in the range similar to that or water or higher.
  • compositions and formulations according to the present disclosure has a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m, such as in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • compositions and formulations of the disclosure may exclude, or, may not comprise a surfactant.
  • compositions of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • surfactants that are excluded include: PEG
  • compositions and formulations of the disclosure may further comprise purified water for injection.
  • the amount of the water may vary depending upon, for example, a fill volume required for the particular high-efficiency nebulizer used.
  • compositions of the disclosure comprise purified water for injection in a quantum sufficiat (q.s.).
  • compositions and formulations of the disclosure may have an osmolality of between about 100 mOsm/kg and about 200 mOsm/kg, inclusive of the endpoints. Compositions and formulations of the disclosure may have an osmolality of between about 125 mOsm/kg and about 135 mOsm/kg, inclusive of the endpoints. Compositions and formulations of the disclosure may have an osmolality of between about 100 mOsm/kg and about 125 mOsm/kg, inclusive of the endpoints. Compositions and formulations of the disclosure may have an osmolality of between about 100 mOsm/kg and about 135 mOsm/kg, inclusive of the endpoints.
  • compositions and formulations of the disclosure may have an osmolality of about 100 mOsm/kg. Compositions and formulations of the disclosure may have an osmolality of about about 125 mOsm/kg. Compositions and formulations of the disclosure may have an osmolality of about 135 mOsm/kg. Compositions and formulations of the disclosure may have an osmolality of about 200 mOsm/kg.
  • compositions and formulations of the disclosure may be in the form of a solution having a fill volume of about 0.1 mL to about 5 mL.
  • Compositions and formulations of the disclosure may be in the form of an aqeuous solution having a fill volume of about 0.1 mL, about 0.5 mL, about 1 mL, about 1.5 mL, about 2 mL, about 2.5 mL, about 3 mL, about 3.5 mL, about 4 mL, about 4.5 mL, or about 5 mL.
  • compositions and formulations of the disclosure may comprise from about 5 mg to about 80 mg of cromolyn sodium, inclusive of the endpoints.
  • Compositions and formulations of the disclosure may comprise from about 36 mg to about 44 mg of cromolyn sodium, inclusive of the endpoints.
  • Nebulizers administering a composition or formulation of the disclosure may provide an aerosol having a respirable fraction ⁇ 3.3 ⁇ m as measured by USP ⁇ 1601> of at least about 30% and a respirable fraction ⁇ 5 ⁇ m as measured by USP ⁇ 1601> of at least about 65%.
  • Nebulizers administering a composition or formulation of the disclosure may provide an aerosol having a respirable fraction ⁇ 3.3 ⁇ m as measured by USP ⁇ 1601> of at least about 45% and a respirable fraction ⁇ 5 ⁇ m as measured by USP ⁇ 1601> of at least about 75%.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer may result in primarily lung deposition, and minimal deposition in other respiratory tracts, of the administered aerosol.
  • sedimentation is the major mechanism of deposition of the aerosol.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer provides a lung deposition (deposited lung dose) of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, about 20% to about 40%, about 25% to about 35%, about 25% to about 30%, about 25% to about 75%, about 30% to about 50%, about 35% to about 90%, about 40% to about 80%, about 40% to about 60%, about 50% to about 60%, about 50% to about 70%, or about 60% to about 75% based on the nominal dose of the composition.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer may produce in the subject an AUC (0- ⁇ ) of the cromolyn sodium greater than about 150 ng*hr/mL, a C max of the cromolyn sodium greater than about 50 ng/mL, and a deposited lung dose of cromolyn sodium greater than about 4 mg.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer may produce in the subject an AUC (0- ⁇ ) of the cromolyn sodium greater than about 175 ng*hr/mL, a C max of the cromolyn sodium greater than about 60 ng/mL, and a deposited lung dose of the cromolyn sodium greater than about 4 mg.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer may produce in the subject an AUC (0- ⁇ ) of the cromolyn sodium greater than about 100 ng*hr/mL, a C max of the cromolyn sodium greater than about 40 ng/mL, and a deposited lung dose of the cromolyn sodium greater than about 4 mg.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is between about 120 ng*hr/mL and about 350 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is within 80% to 125% of about 340 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0-6) of the cromolyn sodium that is between about 120 ng*hr/mL and about 350 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0-6) of the cromolyn sodium that is within 80% to 125% of about 237 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a nebulizer may produce in a subject a C max of the cromolyn sodium of between about 40 ng/mL and about 150 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a nebulizer may produce in a subject a C max of the cromolyn sodium that is within 80% to 125% of about 85 ng/mL, or about 75 ng/mL, or about 82 ng/mL, or about 93 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is between about 250 ng*hr/mL and about 1000 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is within 80% to 125% of about 542 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0-6) of the cromolyn sodium that is between about 200 ng*hr/mL and about 700 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0-6) of the cromolyn sodium that is within 80% to 125% of about 389 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a nebulizer may produce in a subject a C max of the cromolyn sodium of between about 50 ng/mL and about 250 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a nebulizer may produce in a subject C max of the cromolyn sodium that is within 80% to 125% of about 134 ng/mL, or about 119 ng/mL, or about 148 ng/mL, or about 157 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is between about 300 ng*hr/mL and about 800 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a nebulizer may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is within 80% to 125% of about 526 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a nebulizer may produce in a subject a C max of the cromolyn sodium of between about 90 ng/mL and about 450 ng/mL.
  • administration of pharmaceutical compositions of the disclosure with a dry powder inhaler may produce in the subject an AUC (0- ⁇ ) of the cromolyn sodium greater than about 150 ng*hr/mL, a C max of the cromolyn sodium greater than about 50 ng/mL, and a deposited lung dose of cromolyn sodium greater than about 4 mg.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer may produce in the subject an AUC (0- ⁇ ) of the cromolyn sodium greater than about 175 ng*hr/mL, a C max of the cromolyn sodium greater than about 60 ng/mL, and a deposited lung dose of the cromolyn sodium greater than about 4 mg.
  • administration of pharmaceutical compositions of the disclosure with a nebulizer may produce in the subject an AUC (0- ⁇ ) of the cromolyn sodium greater than about 100 ng*hr/mL, a C max of the cromolyn sodium greater than about 40 ng/mL, and a deposited lung dose of the cromolyn sodium greater than about 4 mg.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is between about 120 ng*hr/mL and about 350 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is within 80% to 125% of about 340 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0-6) of the cromolyn sodium that is between about 120 ng*hr/mL and about 350 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0-6) of the cromolyn sodium that is within 80% to 125% of about 237 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a dry powder inhaler may produce in a subject a C max of the cromolyn sodium of between about 40 ng/mL and about 150 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 40 mg of cromolyn sodium with a dry powder inhaler may produce in a subject a C max of the cromolyn sodium that is within 80% to 125% of about 85 ng/mL, or about 75 ng/mL, or about 82 ng/mL, or about 93 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is between about 250 ng*hr/mL and about 1000 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is within 80% to 125% of about 542 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0-6) of the cromolyn sodium that is between about 200 ng*hr/mL and about 700 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0-6) of the cromolyn sodium that is within 80% to 125% of about 389 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a dry powder inhaler may produce in a subject a C max of the cromolyn sodium of between about 50 ng/mL and about 250 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 60 mg of cromolyn sodium with a dry powder inhaler may produce in a subject C max of the cromolyn sodium that is within 80% to 125% of about 134 ng/mL, or about 119 ng/mL, or about 148 ng/mL, or about 157 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is between about 300 ng*hr/mL and about 800 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a dry powder inhaler may produce in a subject an AUC (0- ⁇ ) of the cromolyn sodium that is within 80% to 125% of about 526 ng*hr/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a dry powder inhaler may produce in a subject a C max of the cromolyn sodium of between about 90 ng/mL and about 450 ng/mL.
  • administration of pharmaceutical compositions of the disclosure comprising about 80 mg of cromolyn sodium with a dry powder inhaler may produce in a subject a C max of the cromolyn sodium that is within 80% to 125% of about 236 ng/mL.
  • the pharmaceutical composition is administered daily. In certain embodiments, the pharmaceutical composition is administered once per day. In certain embodiments, the pharmaceutical composition is administered twice per day. In certain embodiments, the pharmaceutical composition is administered three times per day. In certain embodiments, the pharmaceutical composition is administered four times per day. In certain embodiments, the pharmaceutical composition is administered five times per day.
  • the pharmaceutical composition is administered three times per day for at least 7 days. In certain embodiments, the pharmaceutical composition is administered three times per day for at least 14 days. In certain embodiments, the pharmaceutical composition is administered three times per day as a daily maintenance therapy (e.g. at least 7 or at least 14 days without a limit for the total length of treatment).
  • a daily maintenance therapy e.g. at least 7 or at least 14 days without a limit for the total length of treatment.
  • the pharmaceutical composition may be administered as a combination therapy with any other therapeutic composition for the treatment of chronic cough associated or due to a diagnosis of IPF in a subject.
  • FIG. 1 is a series of graphs showing the average number of daytime coughs for each subject in Example 1 following treatment with either PA101 or with one of two placebo treatments.
  • FIG. 2 is a series of graphs showing the total number of daytime coughs for each subject in Example 1 following treatment with either PA101 or with one of two placebo treatments.
  • FIG. 3 is a graph depicting pulmonary function (measured as Forced Expiratory Volume in One Second (FEV1)) as a function of time for each of the treatment groups described in Example 1.
  • FEV1 Forced Expiratory Volume in One Second
  • FIG. 4 is a schematic diagram of the design of the Phase II study described in Example 4.
  • the average number of daytime coughs per hour is a primary efficacy endpoint of this phase II study.
  • FIG. 6 is a graph showing the mean change from baseline of the average number of daytime coughs per hour as a function of time in both placebo-treated and PA101-treated subjects at baseline, Day 7, and Day 14 of the study described in Example 4.
  • FIG. 7 is a pair of graphs demonstrating a placebo-adjusted reduction in cough (left-hand graph), expressed as a percent change from baseline in the daytime average cough/hour at Day 14 for placebo versus PA101-treated subjects of the study described in Example 4 and a PA101/placebo LS mean ratio (95% CI) for this reduction in cough (right-hand graph), expressed as a change in the log transformed daytime average cough/hour at Day 14 for placebo versus PA101-treated subjects of the study described in Example 4.
  • FIG. 8 is a graph showing the PA101/placebo LS mean ratio (95% CI) for the reduction in daytime cough in PA101-treated subjects at Days 7 and 14 (see Example 4).
  • FIG. 9 is a pair of graphs depicting the average daytime coughs per hour for each subject in each of the placebo and PA101 treated groups at either baseline or day 14 of the study described in Example 4.
  • a particular subject is being administered one or more other IPF treatments, such as pirfenidone or nintedanib esylate while being administered at least one formulation disclosed herein that comprises cromolyn sodium.
  • a particular subject is being administered one or more other IPF treatments, such as pirfenidone or nintedanib esylate while being administered at least one formulation disclosed herein that comprises cromolyn sodium.
  • FIG. 12 is a graph showing the nighttime average coughs per hour in (coughs/hour) as a function of time in both placebo-treated and PA101-treated subjects at baseline, Day 7, and Day 14 of the study described in Example 4.
  • the average number of nighttime coughs per hour is a secondary efficacy endpoint of this phase II study.
  • FIG. 13 is a graph showing the mean change from baseline of the average number of nighttime coughs per hour as a function of time in both placebo-treated and PA101-treated subjects at Day 14 of the study described in Example 4.
  • FIG. 14 is a graph showing the average number of coughs (coughs/hour) in a 24-hour period as a function of time in both placebo-treated and PA101-treated subjects at baseline, Day 7, and Day 14 of the study described in Example 4.
  • the average number of coughs per hour in a 24-hour period is a secondary efficacy endpoint of this phase II study.
  • FIG. 15 is a graph demonstrating placebo-adjusted reduction in coughs during a 24-hour period, expressed as a percent change from baseline in the average coughs/hour during a 24-hour period at Days 7 and 14 for placebo versus PA101-treated subjects of the study described in Example 4.
  • FIG. 16 is a graph showing the PA101/placebo LS mean ratio (95% CI) for the placebo-adjusted reduction in coughs, expressed as a change in the log transformed average coughs/hour during a 24-hour period at Days 7 and 14 for placebo versus PA101-treated subjects of the study described in Example 4.
  • FIG. 17 is a pair of graphs demonstrating a placebo-adjusted reduction in cough (left-hand graph), expressed as a percent change from baseline in the 24-hour average cough/hour at Day 14 for placebo versus PA101-treated subjects of the study described in Example 4 and a PA101/placebo LS mean ratio (95% CI) for this reduction in cough (right-hand graph), expressed as a change in the log transformed 24-hour average cough/hour at Day 14 for placebo versus PA101-treated subjects of the study described in Example 4.
  • FIG. 18 is a pair of graphs depicting a 24-hour cough profile for a subject with chronic cough due to IPF receiving either placebo or PA101 as part of the Phase II study described in Example 4.
  • FIG. 19 is a pair of graphs showing the results of the Responder Analysis from Example 4. LCQ and VAS scores were compared in Responders from this study at baseline and day 14 of treatment with PA101.
  • FIG. 20 is a schematic diagram of the design of the study described in Example 5.
  • FIG. 21 is a pair of graphs depicting the average daytime coughs per hour for each subject in each of the placebo and PA101 treated groups at either baseline or day 14 of the study described in Example 5.
  • FIG. 22 is a graph showing the average number of 24-hour coughs (coughs/hour) as a function of time in both placebo-treated and PA101-treated subjects at baseline, Day 7, and Day 14 of the study described in Example 5.
  • the average number of 24-hour coughs per hour is a secondary efficacy endpoint of this phase II study.
  • FIG. 23 is a graph showing the PA101/placebo LS mean ratio (95% CI) for the reduction in daytime cough in PA101-treated subjects at Days 7 and 14 (see Example 5).
  • FIG. 24 is a graph providing the results of a responder analysis for daytime cough, expressed as the percentage (%) of subjects in the study described in Example 5 who experienced a percentage (%) reduction in daytime average coughs/hour compared to baseline.
  • FIG. 25 is a graph showing the PA101/placebo LS mean ratio (95% CI) for the reduction in cough during a 24-hour period in PA101-treated subjects at Days 7 and 14 (see Example 5).
  • FIG. 26 is a pair of graphs showing a Responder Analysis for daytime average cough/hour for subjects with chronic cough due to IPF (Example 4) versus subjects with chronic idiopathic cough (CIC) (Example 5).
  • FIG. 27 is a pair of graphs showing a Responder Analysis for 24-hour average cough/hour for subjects with chronic cough due to IPF (Example 4) versus subjects with chronic idiopathic cough (CIC) (Example 5).
  • FIG. 28 is a graph showing the log transformed daytime average cough/hour subjects with chronic cough due to IPF (Example 4) versus subjects with chronic idiopathic cough (CIC) (Example 5).
  • FIG. 29 is a graph showing the log transformed 24-hour average cough/hour subjects with chronic cough due to IPF (Example 4) versus subjects with chronic idiopathic cough (CIC) (Example 5).
  • compositions of the disclosure comprising cromolyn sodium and an ionic osmotic agent are safe and efficacious for the treatment of chronic cough due to IPF.
  • Subjects treated with the compositions and formulations provided in the disclosure demonstrate a statistically significant and medically relevant improvement in objective cough rates after 14 days of treatment compared to those subjects who received a placebo. These subjects had refractory chronic cough associated with IPF, each of them unable to find relief with the currently-available treatments (not including the formulations and methods of the present disclosure).
  • cough is the most common complaint for which subjects seek medical attention and is the second most common reason for a general medical examination, accounting for more than 26 million office visits annually (National Center for Health Statistics. National Ambulatory Medical Care Survey: 2008).
  • Upper respiratory tract infection i.e. the common cold
  • COPD chronic obstructive pulmonary disease
  • IPF idiopathic pulmonary fibrosis
  • Cough serves a potentially beneficial purpose by clearing the airways of excessive mucus, irritants, or abnormal substances such as edema fluid or pus.
  • productive cough may serve a useful function
  • coughing can also lead to a variety of problems, including exhaustion (57%), feeling self, conscious (55%), insomnia (45%), changes in lifestyle (45%), musculoskeletal pain (45%), hoarseness (43%), excessive perspiration (42%), and urinary incontinence (39%).
  • exhaustion 57%
  • feeling self, conscious 55%
  • insomnia 45%
  • changes in lifestyle 45%
  • musculoskeletal pain 45%
  • hoarseness 45%
  • excessive perspiration 42%
  • urinary incontinence 39%
  • Cough results from activation of myelinated cough receptors and unmyelinated C fibers whose cell bodies are in the jugular and nodose ganglia. Extensive C fiber endings are found under the airway epithelium while cough receptors endings terminate in the mucosa between the epithelium and smooth muscle. Mast cells play an important role in cough, as degranulated mast cells release mediators which can activate C fibers, causing release of Substance P, histamine, serotonin, and proteases. Release of Substance P results in inflammation, vasodilatation, sensitization of nerves, and a hyperactive cough reflex.
  • IPF Idiopathic Pulmonary Fibrosis
  • IPF is a progressive life threatening disease that is characterized anatomically by scarring of the lungs and symptomatically by exertional dyspnea. Its etiology is unknown, and the pathogenic mechanisms involved in its initiation and progression are poorly understood. IPF is characterized by the accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity. Clinical features of IPF include dry cough, breathlessness, restrictive respiratory physiology, end inspiratory crackles, reduced oxygenation, and finger clubbing High-resolution computer tomography (HRCT) shows a distinctive pattern of subpleural shadowing and honeycomb fibrosis later in the disease.
  • HRCT High-resolution computer tomography
  • IPF is a rare lung disorder of unknown etiology impacting approximately 135,000 people in the United States.
  • One common characteristic of IPF appears to be aberrant wound healing that leads to fibrosis.
  • no curative therapy exists.
  • the median survival of a subject with IPF is between three and five years.
  • chronic cough associated with IPF may be defined as a dry non-productive cough (up to 100 coughs per hour) that persists for more than eight weeks despite treatment with standard care.
  • Chronic cough associated with IPF significantly impacts quality of life resulting in, for example, one or more of headache, dizziness, sweating, incontinence, fractured ribs, laryngeal trauma, vomiting, exacerbation of respiratory diseases, loss of sleep, exhaustion, and anxiety.
  • chronic cough associated with IPF significantly impacts psychosocial factors, including, but not limited to, job loss, reluctance to attend public events, and depression.
  • Chronic cough associated with IPF may be an independent predictor of IPF disease progression. Approximately 80% of IPF subjects have a chronic cough. Of those 80%, approximately 40% of those subjects have a form of chronic cough that is refractory to available treatments (available treatments do not include the formulations, compositions or methods of the disclosure).
  • Cough rates may be wide ranging and do not appear to be influenced by the subject's age or gender.
  • cromolyn refers to disodium 5,5′-(2-hydroxypropane-1,3-diyl)bis(oxy)bis(4-oxo-4H-chromene-2-carboxylate) and has the following structure:
  • Cromolyn is also known as sodium cromolyn, cromoglicic acid, disodium cromoglicate (DSCG), sodium cromoglicate, and cromoglicate.
  • Pharmaceutically acceptable salts of cromolyn include but are not limited to cromolyn sodium, cromolyn lysinate, ammonium cromonglycate, and magnesium cromoglycate.
  • Cromolyn sodium is also known as disodium 5,5′-[(2-hydroxytrimethylene)dioxy]bis [4-oxo-4H-1-benzopyran-2-carboxylate].
  • Cromolyn and the pharmaceutically acceptable salts described herein may be prepared as prodrugs.
  • a “prodrug” refers to an agent that is converted into the parent drug in vivo.
  • the prodrug can be designed to alter the metabolic stability or the transport characteristics of a drug, to mask side effects or toxicity, to improve the flavor of a drug, or to alter other characteristics or properties of a drug.
  • the prodrug has improved bioavailability relative to the parent drug.
  • the prodrug has improved solubility in pharmaceutical compositions over the parent drug.
  • prodrugs may be designed as reversible drug derivatives, for use as modifiers to enhance drug transport to site-specific tissues.
  • a prodrug of cromolyn is an ester of cromolyn, which is hydrolyzed to the carboxylic acid, the parent compound.
  • a prodrug comprises a short peptide (polyaminoacid) bonded to an acid group, wherein the peptide is metabolized in vivo to reveal the parent drug.
  • a prodrug upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of cromolyn.
  • a prodrug is enzymatically metabolized by one or more steps or processes to the parent compound.
  • prodrug of cromolyn is used.
  • the prodrug of cromolyn is cromoglicate lisetil.
  • prodrugs of cromolyn are designed by virtue of knowledge of pharmacodynamic processes and drug metabolism in vivo. See, e.g., Nogrady (1985) Medicinal Chemistry A Biochemical Approach , Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401, Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters , Vol. 4, p.
  • cromolyn and pharmaceutically acceptable salts thereof disclosed herein are isotopically-labeled compounds, which are identical to those recited herein, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • isotopes that can be incorporated into the present compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine and chlorine, such as, for example, 2 H, 3 H, 13 C, 14 C, 15 N, 18 O, 17 O 35 S, 18 F, 36 Cl, respectively.
  • isotopically labeled compounds described herein for example those with isotopes such as deuterium, i.e., 2 H, can afford certain therapeutic advantages resulting from greater metabolic stability, such as, for example, increased in vivo half-life or reduced dosage requirements.
  • isotopically labeled cromolyn is co-administered.
  • the pharmaceutically acceptable salt of cromolyn such as cromolyn sodium
  • the pharmaceutically acceptable salt of cromolyn is deuterium-labeled cromolyn sodium.
  • cromolyn and the pharmaceutically acceptable salt thereof described herein are pegylated, wherein one or more polyethylene glycol (PEG) polymers are covalently attached to cromolyn or the pharmaceutically acceptable salt thereof.
  • PEG polyethylene glycol
  • pegylation increases the half-life of the pegylated compound in the body.
  • pegylation increases the hydrodynamic size of the pegylated compound and reduces renal clearance.
  • pegylation increases the solubility of the pegylated compound.
  • Cromolyn and pharmaceutically acceptable salts, prodrugs, and adducts thereof, may be prepared by methods known in the art.
  • Cromolyn or a pharmaceutically acceptable salt thereof may be administered in the methods disclosed herein in a suitable dose or nominal dose as determined by one of ordinary skill in the art.
  • cromolyn or a pharmaceutically acceptable salt thereof is administered at a dosage or nominal dosage of less than about 1 mg/dose, about 1 mg/dose to about 100 mg/dose, about 1 mg/dose to about 120 mg/dose, about 5 mg/dose to about 80 mg/dose, about 20 mg/dose to about 60 mg/dose, about 30 mg/dose to about 50 mg/dose, or greater than about 100 mg/dose.
  • cromolyn or a pharmaceutically acceptable salt thereof is administered in less than about 1 mg, about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg doses, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg doses.
  • cromolyn or a pharmaceutically acceptable salt thereof is administered in about 30 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 40 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 50 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 60 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 70 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 80 mg.
  • cromolyn sodium is administered at a dosage or nominal dosage of less than about 1 mg/dose, about 1 mg/dose to about 100 mg/dose, about 1 mg/dose to about 120 mg/dose, about 5 mg/dose to about 80 mg/dose, about 20 mg/dose to about 60 mg/dose, or about 30 mg/dose to about 50 mg/dose, or greater than about 100 mg/dose.
  • cromolyn sodium is administered in less than about 1 mg, about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg doses, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg doses.
  • cromolyn or a pharmaceutically acceptable salt thereof is administered in about 30 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 40 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 50 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 60 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 70 mg. In certain embodiments, cromolyn or a pharmaceutically acceptable salt thereof is administered in about 80 mg.
  • DSCG has a long history of use for its anti-allergy, anti-inflammatory, and immune-modulating properties as well as its exceptional safety profile.
  • the available formulations of DSCG (that do not include the compositions of the disclosure) are not suitable for use in chronic cough associated with IPF, because the available formulations of DSCG are too limited by poor delivery efficiency and very low bioavailability (approximately 1%).
  • compositions and formulations of the disclosure enhance bioavailability and provide efficacious treatment of the debilitating symptoms of chronic cough associated with IPF.
  • the compositions and formulations of the disclosure achieve significantly higher lung and peripheral distribution than currently available formulations, parameters that are both required for efficacy in treatment of chronic cough associated with IPF.
  • Table 1a provides exemplary, nonlimiting, formulations of the compositions of the disclosure, wherein the amounts of each component of the formulations are expressed as weight percent of the total weight of the formulation.
  • PA101 PA101B PA101B PA101B Component Function (wt %) (wt %) (wt %) (wt %) (wt %) Cromolyn Active Substance 4 2 4 6 Sodium Chloride Osmotic Agent 0.2 0.2 0.2 0.2 EDTA Chelating Agent 0.02 0.02 0.02 0.02 Mannitol Non-ionic Osmotic Agent 1.25 0 0 0 Water for Injection (WFI) Quantum sufficiat (q.s.) q.s. q.s. q.s. q.s. Osmolality (mOsm/kg) Tonicity 200 106 125 135
  • Table 1b provides further exemplary, nonlimiting, formulations of the compositions of the disclosure, wherein the amounts of each component of the formulations are expressed as weight percent of the total weight of the formulation.
  • Cromolyn Sodium sodium Mannitol chloride EDTA Osmolality Formulation (%) (%) (%) (%) (%) (%) (mOsm/kg) 1 2 0 0 0.02 42 2 2 0 0.2 0.02 106 3 2 0 0.4 0.02 170 4 2 0 0.6 0.02 235 5 2 0 0.8 0.02 299 6 4 1.25 0.2 0.02 199 7 4 1 0.2 0.02 183 8 4 0.75 0.2 0.02 169 9 4 0.5 0.2 0.02 154 10 4 0.25 0.2 0.02 139 11 4 0 0.2 0.02 125 12 5 1.25 0.2 0.02 207 13 5 0 0.2 0.02 131 14 5 0 0.25 0.02 147 15 6 1.25 0.2 0.02 214 16 6 0 0.2 0.02 138 17 6 0 0.25 0.02 154
  • PA101B formulations 4% by weight and 6% by weight are each highly concentrated, well-tolerated, room-temperature stable formulations of disodium cromoglycate optimized for delivery via an electronic nebulizer.
  • compositions of the disclosure may comprise an ionic osmolarity or osmolality adjusting agent but, do not comprise a non-ionic osmolarity or osmolality adjusting agent.
  • Ionic osmolarity or osmolality adjusting agents can be selected from, for example, alkali metal salts, such as sodium and potassium salts. Examples of such salts include, but are not limited to, sodium chloride, sodium gluconate, sodium pyruvate, and potassium chloride. It is possible to use a single ionic tonicity-adjusting agent, such as sodium chloride, or a mixture of such agents.
  • the salts may be either added or formed in situ due to a salt formation process.
  • the non-ionic osmolarity or osmolality adjusting agent is mannitol.
  • the non-ionic osmolarity or osmolality adjusting agent can be selected from, for example, the group of carbohydrates.
  • carbohydrates that can be used for isotonisation include, but are not limited to, sugars such as glucose, lactose, sucrose and trehalose, and sugar alcohols such as mannitol, xylitol, sorbitol, and isomaltol.
  • the non-ionic osmolarity or osmolality adjusting agent is not propylene glycol, a cyclodextrin or mannitol.
  • the disclosure provides a pharmaceutically acceptable aerosol for the treatment of chronic cough in a subject having idiopathic pulmonary fibrosis (IPF), comprising droplets of an aqueous solution comprising (i) from about 2% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent comprising (a) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (b) optionally salts of ethylenediaminetetraacetic acid (EDTA), wherein said aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, and wherein said treatment of said chronic cough in said subject is achieved via delivery of a therapeutically effective amount of cromolyn sodium to the lungs of the subject by said subject orally inhaling said pharmaceutically acceptable aerosol.
  • IPF idiopathic pulmonary fibrosis
  • the pharmaceutically acceptable aerosol comprises droplets of an aqueous solution comprising salts of EDTA, wherein the salts are selected from sodium EDTA.
  • the pharmaceutically aerosols wherein the aqueous solution contains from about 5 mg to about 80 mg of cromolyn sodium.
  • the pharmaceutically aerosols wherein the aqueous solution contains from about 36 mg to about 44 mg of cromolyn sodium.
  • the pharmaceutically aerosols wherein the aqueous solution contains about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, or about 80 mg of cromolyn sodium.
  • said sodium chloride is at a concentration of between 0.1% to 0.2% by weight, inclusive of the endpoints.
  • the disclosure provides a pharmaceutically acceptable aerosol for the treatment of chronic cough in a subject having idiopathic pulmonary fibrosis (IPF), consisting of droplets of an aqueous solution consisting of (i) from about 2% to about 6% by weight of cromolyn sodium and (ii) an osmolarity adjusting agent consisting of (a) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (b) optionally salts of ethylenediaminetetraacetic acid (EDTA), wherein said aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, and wherein said treatment of said chronic cough in said subject is achieved via delivery of a therapeutically effective amount of cromolyn sodium to the lungs of the subject by said subject orally inhaling said pharmaceutically acceptable aerosol.
  • IPF idiopathic pulmonary fibrosis
  • the pharmaceutically acceptable aerosol comprises droplets of an aqueous solution comprising salts of EDTA, wherein the salts are selected from sodium EDTA.
  • the pharmaceutically aerosols wherein the aqueous solution contains from about 5 mg to about 80 mg of cromolyn sodium.
  • the pharmaceutically aerosols wherein the aqueous solution contains from about 36 mg to about 44 mg of cromolyn sodium.
  • the pharmaceutically aerosols wherein the aqueous solution contains about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, or about 80 mg of cromolyn sodium.
  • said sodium chloride is at a concentration of between 0.1% to 0.2% by weight, inclusive of the endpoints.
  • idiopathic pulmonary fibrosis comprising administering a pharmaceutically acceptable aerosol to said subject by oral inhalation, said pharmaceutically acceptable aerosol acceptable consisting of droplets of an aqueous solution consisting of from about 2% to about 6% by weight of cromolyn sodium, (ii) between about 0.1% and about 0.5% by weight of sodium chloride, inclusive of the endpoints, and (iii) optionally salts of ethylenediaminetetraacetic acid (EDTA).
  • EDTA ethylenediaminetetraacetic acid
  • the pharmaceutically acceptable aerosols wherein said aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%.
  • the pharmaceutically acceptable aerosols wherein said aerosol has a respirable fraction ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 75%.
  • the pharmaceutically acceptable aerosol comprises droplets of an aqueous solution comprising salts of EDTA, wherein the salts are selected from sodium EDTA.
  • the pharmaceutically aerosols wherein the aqueous solution contains from about 5 mg to about 80 mg of cromolyn sodium.
  • the pharmaceutically aerosols wherein the aqueous solution contains from about 36 mg to about 44 mg of cromolyn sodium.
  • the pharmaceutically aerosols wherein the aqueous solution contains about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 31 mg, about 32 mg, about 33 mg, about 34 mg, about 35 mg, about 36 mg, about 37 mg, about 38 mg, about 39 mg, about 40 mg, about 41 mg, about 42 mg, about 43 mg, about 44 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, or about 80 mg of cromolyn sodium.
  • said sodium chloride is at a concentration of between 0.1% to 0.2% by weight, inclusive of the endpoints.
  • formulations administered in the methods disclosed herein produce in a subject AUC (0- ⁇ ) of cromolyn or a pharmaceutically acceptable salt thereof greater than about 100 ng*hr./mL, greater than about 110 ng*hr./mL, greater than about 120 ng*hr./mL, greater than about 130 ng*hr./mL, greater than about 140 ng*hr./mL, greater than about 150 ng*hr./mL, greater than about 160 ng*hr./mL, greater than about 170 ng*hr./mL, greater than about 180 ng*hr./mL, greater than about 190 ng*hr./mL, greater than about 200 ng*hr./mL, greater than about 225 ng*hr./mL, greater than about 250 ng*hr./mL, greater than about 275 ng*hr./mL, greater than about 300 ng*hr./mL, greater than
  • formulations administered in the methods disclosed herein produce in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 100 ng*hr./mL, greater than about 110 ng*hr./mL, greater than about 120 ng*hr./mL, greater than about 130 ng*hr./mL, greater than about 140 ng*hr./mL, greater than about 150 ng*hr./mL, greater than about 160 ng*hr./mL, greater than about 170 ng*hr./mL, greater than about 180 ng*hr./mL, greater than about 190 ng*hr./mL, greater than about 200 ng*hr./mL, greater than about 225 ng*hr./mL, greater than about 250 ng*hr./mL, greater than about 275 ng*hr./mL, greater than about 300 ng*hr./mL
  • formulations administered in the methods disclosed herein produce in a subject AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof of about 100 ng*hr./mL, about 110 ng*hr./mL, about 120 ng*hr./mL, about 130 ng*hr./mL, about 140 ng*hr./mL, about 150 ng*hr./mL, about 160 ng*hr./mL, about 170 ng*hr./mL, about 180 ng*hr./mL, about 190 ng*hr./mL, about 200 ng*hr./mL, about 225 ng*hr./mL, about 250 ng*hr./mL, about 275 ng*hr./mL, about 300 ng*hr./mL, about 325 ng*hr./mL, about 350 ng*hr./mL, about 375
  • formulations administered in the methods disclosed herein produce in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof of about 100 ng*hr./mL, about 110 ng*hr./mL, about 120 ng*hr./mL, about 130 ng*hr./mL, about 140 ng*hr./mL, about 150 ng*hr./mL, about 160 ng*hr./mL, about 170 ng*hr./mL, about 180 ng*hr./mL, about 190 ng*hr./mL, about 200 ng*hr./mL, about 225 ng*hr./mL, about 250 ng*hr./mL, about 275 ng*hr./mL, about 300 ng*hr./mL, about 325 ng*hr./mL, about 350 ng*hr./mL, about 375
  • formulations administered in the methods disclosed herein produce in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 100 ng*hr./mL, greater than about 110 ng*hr./mL, greater than about 120 ng*hr./mL, greater than about 130 ng*hr./mL, greater than about 140 ng*hr./mL, greater than about 150 ng*hr./mL, greater than about 160 ng*hr./mL, greater than about 170 ng*hr./mL, greater than about 180 ng*hr./mL, greater than about 190 ng*hr./mL, greater than about 200 ng*hr./mL, greater than about 225 ng*hr./mL, greater than about 250 ng*hr./mL, greater than about 275 ng*hr./mL, greater than about 300 ng*hr./mL, greater than about 325 ng*
  • formulations administered in the methods disclosed herein produce in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 100 ng*hr./mL, greater than about 110 ng*hr./mL, greater than about 120 ng*hr./mL, greater than about 130 ng*hr./mL, greater than about 140 ng*hr./mL, greater than about 150 ng*hr./mL, greater than about 160 ng*hr./mL, greater than about 170 ng*hr./mL, greater than about 180 ng*hr./mL, greater than about 190 ng*hr./mL, greater than about 200 ng*hr./mL, greater than about 225 ng*hr./mL, greater than about 250 ng*hr./mL, greater than about 275 ng*hr./mL, greater than about 300 ng*hr./mL, greater than about 325 ng*
  • formulations administered in the methods disclosed herein produce in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 100 ng*hr./mL, about 110 ng*hr./mL, about 120 ng*hr./mL, about 130 ng*hr./mL, about 140 ng*hr./mL, about 150 ng*hr./mL, about 160 ng*hr./mL, about 170 ng*hr./mL, about 180 ng*hr./mL, about 190 ng*hr./mL, about 200 ng*hr./mL, about 225 ng*hr./mL, about 250 ng*hr./mL, about 275 ng*hr./mL, about 300 ng*hr./mL, about 325 ng*hr./mL, about 350 ng*hr./mL, about 375 ng*hr./mL
  • formulations administered in the methods disclosed herein produce in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 100 ng*hr./mL, about 110 ng*hr./mL, about 120 ng*hr./mL, about 130 ng*hr./mL, about 140 ng*hr./mL, about 150 ng*hr./mL, about 160 ng*hr./mL, about 170 ng*hr./mL, about 180 ng*hr./mL, about 190 ng*hr./mL, about 200 ng*hr./mL, about 225 ng*hr./mL, about 250 ng*hr./mL, about 275 ng*hr./mL, about 300 ng*hr./mL, about 325 ng*hr./mL, about 350 ng*hr./mL, about 375 ng*hr./mL
  • formulation administered in the methods disclosed herein produce in a subject a Cmax of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/mL, greater than about 230 ng/mL, greater than about 240 ng/mL, greater than about 40
  • formulations administered in the methods disclosed herein produce in a subject a C max of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/mL, greater than about 230 ng/mL, greater than about 240 ng/mL,
  • formulations administered in the methods disclosed herein produce in a subject a Cmax of cromolyn or a pharmaceutically-acceptable salt thereof of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, 260 ng/mL, about 270 ng/mL, about 280 ng/mL, about 290 ng/mL, about 300 ng/mL,
  • formulations administered in the methods disclosed herein produce in a subject a C max of cromolyn or a pharmaceutically-acceptable salt thereof of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, 260 ng/mL, about 270 ng/mL, about 280 ng/mL, about 290 ng/mL, about 300 ng/mL,
  • formulations administered in the methods disclosed herein produce in a subject a Cmax of cromolyn sodium greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/mL, greater than about 230 ng/mL, greater than about 240 ng/mL, greater than about 250 ng/mL
  • formulations administered in the methods disclosed herein produce in a subject a C max of cromolyn sodium greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/mL, greater than about 230 ng/mL, greater than about 240 ng/mL, greater than about 250 ng/mL
  • formulations administered in the methods disclosed herein produce in a subject a Cmax of cromolyn sodium of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, 260 ng/mL, about 270 ng/mL, about 280 ng/mL, about 290 ng/mL, about 300 ng/mL, about 310 ng/mL,
  • formulations administered in the methods disclosed herein produce in a subject a C max of cromolyn sodium of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, 260 ng/mL, about 270 ng/mL, about 280 ng/mL, about 290 ng/mL, about 300 ng/mL, about 310 ng/mL,
  • Cromolyn or a pharmaceutically acceptable salt thereof may be administered to a subject in the methods disclosed herein with an inhalation device, e.g., a nebulizer.
  • an inhalation device e.g., a nebulizer.
  • Cromolyn or a pharmaceutically acceptable salt thereof may be formulated into any suitable dosage form, including but not limited to aerosols, aqueous oral dispersions, self-emulsifying dispersions, liposomal dispersions, pegylated liposomes, liquids, elixirs, suspensions, aerosols, controlled release formulations, lyophilized formulations, powders, delayed release formulations, extended release formulations, multiparticulate formulations or mixed immediate release formulations.
  • Such formulations may be manufactured in a conventional manner, such as, by way of example only, conventional mixing, dissolving, or granulating processes.
  • the formulations disclosed herein may include one or more inactive ingredients or pharmaceutical excipients that provide suitable properties of the formulation.
  • inactive ingredients may include one or more of the following classes.
  • albumin refers to a family of globular proteins, the most common of which is serum albumin. Albumins are commonly found in blood plasma and function to regulate colloidal osmotic pressure of the blood. Albumin proteins found in the plasma bind some pharmaceutical compounds to form complexes. Complexation of albumin with pharmaceutical compounds, e.g., cromolyn or a pharmaceutical salt thereof, can influence the pharmaceutical compounds' plasma half-life and/or biological half-life in the body by preventing metabolism and/or excretion of the complexed compounds.
  • compositions disclosed herein include albumin and cromolyn or a pharmaceutical salt thereof (e.g. cromolyn sodium).
  • Antifoaming agents reduce foaming during processing which can result in coagulation of aqueous dispersions, bubbles in the finished film, or generally impair processing.
  • Exemplary anti-foaming agents include silicon emulsions or sorbitan sesquoleate
  • Antioxidants include, for example, butylated hydroxytoluene (BHT), sodium ascorbate, ascorbic acid, sodium metabisulfite and tocopherol. In certain embodiments, antioxidants enhance chemical stability where required.
  • BHT butylated hydroxytoluene
  • antioxidants enhance chemical stability where required.
  • Binders impart cohesive qualities and include, e.g., alginic acid and salts thereof; cellulose derivatives such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®), and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylose; magnesium aluminum silicate; polysaccharide acids; bentonites; gelatin; polyvinylpyrrolidone/vinyl acetate copolymer; crosspovidone; povidone; starch; pregelatinized starch; tragacanth, dextrin, a sugar, such as sucrose (e.g., Dipac®), glucose, dextrose, molasses, mannitol, sorbitol, xylitol (e.g., cellulose
  • Carriers or “carrier materials” include any commonly used excipients in pharmaceutics and should be selected on the basis of compatibility with cromolyn or a pharmaceutically acceptable salt thereof and the release profile properties of the desired dosage form.
  • exemplary carrier materials include, e.g., binders, suspending agents, disintegration agents, filling agents, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like.
  • “Pharmaceutically compatible carrier materials” may include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerine, magnesium silicate, polyvinylpyrrollidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphotidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugars sodium stearoyl lactylate, carrageenan, monoglyceride, diglyceride, pregelatinized starch, and the like.
  • PVP polyvinylpyrrollidone
  • Disposing agents and/or “viscosity modulating agents” include materials that control the diffusion and homogeneity of a drug through liquid media or a granulation method or blend method. In certain embodiments, these agents also facilitate the effectiveness of a coating or eroding matrix.
  • Exemplary diffusion facilitators/dispersing agents include, e.g., hydrophilic polymers, electrolytes, Tween® 60 or 80, PEG, Tyloxapol, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and the carbohydrate-based dispersing agents such as, for example, hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcelluloses (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinyl pyrrolidone/vinyl acetate copolymer (S630), 4-(1,
  • Plasticizcers such as cellulose or triethyl cellulose can also be used as dispersing agents.
  • Dispersing agents particularly useful in liposomal dispersions and self-emulsifying dispersions are dimyristoyl phosphatidylcholine, natural phosphatidyl choline from eggs, natural phosphatidyl glycerol from eggs, cholesterol and isopropyl myristate.
  • “Diluent” refers to chemical compounds that are used to dilute the compound of interest (i.e. cromolyn or a pharmaceutically acceptable salt thereof) prior to delivery. Diluents can also be used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions, including, but not limited to, a phosphate buffered saline solution, are utilized as diluents in the art, and can also provide pH control or maintenance. In certain embodiments, diluents increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling.
  • Such compounds include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose-based diluents, confectioner's sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like.
  • Avicel® di
  • “Flavoring agents” and/or “sweeteners” useful in the formulations described herein include, e.g., acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana, Bavarian cream, berry, black currant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dentomint, dextrose, eucalyptus , eugenol, fructose, fruit punch, ginger, glycyrrhetinate, glycyrrhiza (licorice) syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glyrrhizinate (MagnaSweet®), maltol, mannitol, maple, marshmallow
  • “Lubricants” and “glidants” are compounds that prevent, reduce or inhibit adhesion or friction of materials.
  • Exemplary lubricants include, e.g., stearic acid, calcium hydroxide, talc, sodium stearyl fumerate, a hydrocarbon such as mineral oil, or hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, glycerol, talc, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol (e.g., PEG-4000) or a methoxypolyethylene glycol such as CarbowaxTM, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium lauryl sulfate
  • Plasticizers are compounds used to soften the microencapsulation material or film coatings to make them less brittle. Suitable plasticizers include, e.g., polyethylene glycols such as PEG 300, PEG 400, PEG 600, PEG 1450, PEG 3350, and PEG 800, stearic acid, propylene glycol, oleic acid, triethyl cellulose and triacetin. In certain embodiments, plasticizers can also function as dispersing agents or wetting agents.
  • compositions provided herein may also include one or more preservatives to inhibit microbial activity.
  • Suitable preservatives include mercury-containing substances such as merfen and thiomersal; stabilized chlorine dioxide; octinidine; and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide and cetylpyridinium chloride.
  • Solubilizers include compounds such as triacetin, triethylcitrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium doccusate, vitamin E TPGS, polysorbates (Tweens) dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, hydroxypropyl cyclodextrins, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide and the like.
  • Stabilizers include compounds such as any antioxidation agents, e.g., citric acid, EDTA and pharmaceutically acceptable salts thereof, buffers, acids, preservatives and the like.
  • “Suspending agents” include compounds such as polyvinylpyrrolidone, e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, vinyl pyrrolidone/vinyl acetate copolymer (S630), polyethylene glycol, e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 7000 to about 5400, sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose acetate stearate, polysorbate-80, hydroxyethylcellulose, sodium alginate, gums, such as, e.g., gum tragacanth and gum acacia, guar gum, xanthans, including xanthan gum, sugars, cellulosics, such as, e
  • “Surfactants” include compounds such as sodium lauryl sulfate, sodium docusate, Tween 60 or 80, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, e.g., Pluronic® (BASF), and the like.
  • Pluronic® Pluronic®
  • surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40. In certain embodiments, surfactants may be included to enhance physical stability or for other purposes.
  • “Viscosity enhancing agents” include, e.g., methyl cellulose, xanthan gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose acetate stearate, hydroxypropylmethyl cellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosans, and combinations thereof.
  • Weight agents include compounds such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium doccusate, triacetin, Tween 80, vitamin E TPGS, ammonium salts and the like.
  • inactive ingredients there is considerable overlap between classes of inactive ingredients.
  • the above-listed ingredients should be taken as merely exemplary, and not limiting, of the types of inactive ingredients that can be included in formulations described herein.
  • the amounts of such inactive ingredients can be readily determined by one skilled in the art, according to the particular properties desired.
  • Liquid formulation dosage forms for oral administration can be aqueous suspensions selected from the group including, but not limited to, pharmaceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2 nd Ed ., pp. 754-757 (2002).
  • the liquid dosage forms may include additives, such as: (a) disintegrating agents; (b) dispersing agents; (c) wetting agents; (d) at least one preservative, (e) viscosity enhancing agents, (f) at least one sweetening agent, and (g) at least one flavoring agent.
  • the aqueous dispersions can further include a crystalline inhibitor.
  • systemically effective amounts of cromolyn or a pharmaceutically-acceptable salt thereof are achieved with liquid oral formulations by including permeation enhancers in the liquid oral formulations.
  • disintegrating agents for use in the aqueous suspensions and dispersions include, but are not limited to, a starch, e.g., a natural starch such as corn starch or potato starch, a pregelatinized starch such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®; a cellulose such as a wood product, methylcrystalline cellulose, e.g., Avicel®, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® P100, Emcocel®, Vivacel®, Ming Tia®, and Solka-Floc®, methylcellulose, croscarmellose, or a cross-linked cellulose, such as cross-linked sodium carboxymethylcellulose (Ac-Di-Sol®), cross-linked carboxymethylcellulose, or cross-linked croscarmellose; a cross-linked starch such as sodium starch glycolate; a cross-linked polymer such as sodium star
  • the dispersing agents suitable for the aqueous suspensions and dispersions described herein include, for example, hydrophilic polymers, electrolytes, Tween® 60 or 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and the carbohydrate-based dispersing agents such as, for example, hydroxypropylcellulose and hydroxypropyl cellulose ethers (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers (e.g.
  • HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M carboxymethylcellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylmethyl-cellulose phthalate, hydroxypropylmethyl-cellulose acetate stearate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone/vinyl acetate copolymer (Plasdone®, e.g., S-630), 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, F88®, and F108®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copo
  • the dispersing agent is selected from a group not comprising one of the following agents: hydrophilic polymers; electrolytes; Tween® 60 or 80; PEG; polyvinylpyrrolidone (PVP); hydroxypropylcellulose and hydroxypropyl cellulose ethers (e.g., HPC, HPC-SL, and HPC-L); hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers (e.g.
  • HPMC K100, HPMC K4M, HPMC K15M, HPMC K100M, and Pharmacoat® USP 2910 (Shin-Etsu)); carboxymethylcellulose sodium; methylcellulose; hydroxyethylcellulose; hydroxypropylmethyl-cellulose phthalate; hydroxypropylmethyl-cellulose acetate stearate; non-crystalline cellulose; magnesium aluminum silicate; triethanolamine; polyvinyl alcohol (PVA); 4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde; poloxamers (e.g., Pluronics F68®, F88®, and F108®, which are block copolymers of ethylene oxide and propylene oxide); or poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®).
  • Pluronics F68®, F88®, and F108® which are block copolymers of ethylene oxide and propylene oxide
  • poloxamines
  • Wetting agents suitable for the aqueous suspensions and dispersions described herein include, but are not limited to, cetyl alcohol, glycerol monostearate, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens® such as e.g., Tween 20® and Tween 80® (ICI Specialty Chemicals)), and polyethylene glycols (e.g., Carbowaxs 3350® and 1450®, and Carbopol 934® (Union Carbide)), oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, vitamin E TPGS, sodium taurocholate, simethicone, phosphotidy
  • compositions and formulations of the disclosure may have a surface tension effective for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli.
  • the compositions and formulations of the disclosure may have a surface tension in the range similar to that or water or higher.
  • the compositions and formulations according to the present disclosure has a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • the compositions and formulations has a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • compositions and formulations of the disclosure may exclude, or, may not comprise a surfactant.
  • compositions of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • surfactants that are excluded include: PEG
  • an “inhalation device,” as used herein, refers to any device that is capable of administering a drug formulation to the respiratory airways of a subject.
  • Inhalation devices include conventional inhalation devices such as nebulizers, metered dose inhalers (MDIs), dry powder inhalers (DPIs), jet nebulizers, ultrasonic wave nebulizers, heat vaporizers, and soft mist inhalers.
  • Inhalation devices also include nebulizers. Nebulizers, metered dose inhalers, and soft mist inhalers deliver pharmaceuticals by forming an aerosol which includes droplet sizes that can easily be inhaled.
  • the aerosol can be used by a subject within the bounds of an inhalation therapy, whereby the cromolyn or a pharmaceutically-acceptable salt thereof reaches the subject's respiratory tract upon inhalation.
  • the methods disclosed herein comprise administering to a subject a nominal dose of cromolyn or a pharmaceutically-acceptable salt thereof by an inhalation device, such as a nebulizer.
  • an inhalation device is not a bronchoscope.
  • a composition comprising cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium
  • an inhalation device e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • a composition comprising cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium
  • an inhalation device e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • a composition comprising cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium
  • an inhalation device e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • an inhalation device e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • cromolyn or a pharmaceutically acceptable salt thereof is administered with an inhalation device, e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • an inhalation device e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • an inhalation device e.g., a nebulizer, a dry powder inhaler, a metered dose inhaler, a thermal aerosol inhaler, or an electrohydrodynamic-based solution misting inhaler
  • a systemically effective amount of cromolyn or a pharmaceutically acceptable salt thereof is achieved by delivering the cromolyn or a pharmaceutically acceptable salt thereof in an aerosol generated by a vibrating mesh nebulizer that produces droplets with a MMD of 3.0-4.0 ⁇ m and a GSD of 1.5-1.8.
  • an aerosol is administered through a mouthpiece of a nebulizer using normal tidal breathing.
  • the efficiency of a particular inhalation device can be characterized in many different ways, including by pharmacokinetic properties, lung deposition (deposited lung dose), respirable dose (RD), delivered dose (DD), respirable fraction (RF), respirable drug delivery rate (RDDR), volumetric or mass median diameter (VMD or MMD), mass median aerodynamic diameter (MMAD) in combination with the geometric standard deviation (GSD), and total output rate (TOR), among others.
  • the MMAD and GSD can be measured using a cascade impactor as described in United States Phamacopeia (USP ⁇ 1601>).
  • the DD can be measured by using breath simulation apparatus as described in USP ⁇ 1601>.
  • the RF is derived from measuring the amount of drug deposited on the cascade impactor plates with a particular cut-off particle size, and expressing that as a fraction of the total amount deposited on the cascade impactor plates, the induction port and the filter.
  • RF refers to a distribution of particles of an aerosol indicative of the percentages of the total mass or volume of the aerosol that are contained in particles of certain sizes.
  • Such a mass/volume distribution expressed as the resipirable fraction (RF) is different from a distribution based on the percentages of the total number of particles in the aerosol that have certain particle sizes.
  • a number distribution of particles contained in an aerosol can be markedly different from a mass distribution of the same particles in the same aerosol.
  • the volume of a spherical particle of diameter d is 4/3* ⁇ *(d/2) 3 .
  • the volumes of the 1 ⁇ m, 2 ⁇ m and 3 ⁇ m particles would therefore be 0.52 ⁇ 3 , 4.2 ⁇ 3 , and 14.13 ⁇ 3 .
  • these numbers would also represent the mass of the particles.
  • the 2 ⁇ m particles will constitute 22.3% of the total mass and the 1 ⁇ m particles will be 2.8% of the total mass.
  • the RD is calculated by multiplying the DD by the RF.
  • the TOR is measured by the difference in weight of a nebulizer before and after completion of nebulization divided by the duration of nebulization.
  • VMD or MMD can be measured with a standard laser light scattering apparatus such as the Malvern Spraytec.
  • Pharmacokinetics is concerned with the uptake, distribution, metabolism and excretion of a drug substance in a subject.
  • a pharmacokinetic profile comprises one or more biological measurements designed to measure the absorption, distribution, metabolism and excretion of a drug substance in a subject.
  • One way of visualizing a pharmacokinetic profile is by means of a blood plasma concentration curve, which is a graph depicting mean active ingredient blood plasma concentration in a subject on the Y-axis and time (usually in hours) on the X-axis.
  • Some pharmacokinetic parameters that may be visualized by means of a blood plasma concentration curve include AUC last , AUC (0- ⁇ ) , C max , T 1/2 , and T max .
  • An enhanced pharmacokinetic profile in a subject can be indicated by increased AUC last , AUC (0- ⁇ ) , C max , or T 1/2 , a decreased T max , or an increased T max .
  • Enhanced levels of cromolyn or a pharmaceutically-acceptable salt thereof in the blood plasma of a subject may result in better control of or improved symptoms of chronic cough due to IPF.
  • the deposited lung dose may be expressed as a percentage of the nominal dose that is deposited in the lung of a subject. For example, a lung deposition of 30% means 30% of the nominal dose is deposited in the lung of a subject. Likewise, a lung deposition of 60% means 60% of the nominal dose is deposited in the lung of a subject, and so forth. Lung deposition (deposited lung dose) can be determined using methods of scintigraphy or deconvolution.
  • the deposited lung dose for cromolyn during inhalation can also be determined by measuring the cromolyn sodium content in the urine and multiplying that number by two.
  • RF represents the percentage of the delivered aerosol, or inhaled mass, that penetrates into the gas-exchange region of the lungs.
  • RF may be measured with a cascade impactor or laser diffraction apparatus.
  • RF is expressed herein as the percentage of an aerosol delivered with an inhalation device that has a particular particle diameter or range of particle diameters.
  • RF ( ⁇ 3.3 ⁇ m) refers to the percentage of an aerosol delivered with an inhalation device that has a particle diameter less than or equal to 3.3 ⁇ m.
  • RF (1-5 ⁇ m) and “RF ( ⁇ 5 ⁇ m)” as used herein refer to the percentage of an aerosol delivered with an inhalation device that has a particle diameter in the range of 1 ⁇ m to 5 ⁇ m, or less than 5 ⁇ m, respectively.
  • DD is the portion or percentage of the nominal dose that is actually emitted from the mouthpiece of the device. The difference between the nominal dose and the DD is the amount of drug lost primarily as residues, i.e., the amount of drug remaining in the inhalation device after administration or lost in aerosol form during exhalation.
  • RD is an expression of the delivered mass of drug contained within droplets or particles having a certain diameter emitted from an inhalation device, such as a DPI, MDI, or nebulizer, that are small enough to penetrate into the lung of a subject.
  • the RD is determined by multiplying the DD by the RF.
  • RDDR is the speed at which a respirable dose of the drug is delivered to a subject's lungs.
  • RDDR measured as a function of g/min or mg/min, is determined by dividing the RD by the amount of time necessary for inhalation.
  • the amount of time necessary for inhalation is measured as the amount of time from the first moment of administration of the emitted droplet or powder from the nebulizer, DPI, or MDI until the emitted or delivered droplet or powder of a respirable diameter is delivered to the lung.
  • Aerosol particle/droplet size is one factor determining the deposition of aerosol drugs in the airways.
  • the distribution of aerosol particle/droplet size can be expressed in terms of one or more of VMD/MMAD and GSD.
  • GSD is a dimensionless measure of a droplet size distribution curve relevant for characterizing terms such as VMD, MMD, and MMAD. In general, the smaller the GSD for a particular particle size distribution, the narrower the distribution curve.
  • Inhalation devices may be mechanical or electrical, and include, for example, jet nebulizers, and ultrasonic nebulizers.
  • Jet nebulizers generally utilize compressors to generate compressed air, which breaks the liquid medication into small breathable droplets, which form an aerosolized (atomized) mist.
  • a valve at the top opens, which then allows air into the apparatus, thereby speeding up the mist generation; when the subject breathes out, the top valve closes, thereby slowing down the mist generation while simultaneously permitting the subject to breathe out through the opening of a mouthpiece flap.
  • Some nebulizers may provide the aerosol in a continuous mode (e.g., the eFlow from PARI Pharma Starnberg), by a breath enhanced mode (e.g., the PARI LC Plus or Sprint from PART Starnberg), by breath actuated mode dependent on the breathing pattern of the subject (e.g., the AeroEclipse from Trudell, Canada or the I-Neb from Philips Respironics), or according to given inhalation profile (e.g., the Akita from Activaero, Gmuenden, Germany).
  • a continuous mode e.g., the eFlow from PARI Pharma Starnberg
  • a breath enhanced mode e.g., the PARI LC Plus or Sprint from PART Starnberg
  • breath actuated mode dependent on the breathing pattern of the subject e.g., the AeroEclipse from Trudell, Canada or the I-Neb from Philips Respironics
  • given inhalation profile e.g., the Akit
  • compositions comprising cromolyn or a pharmaceutically-acceptable salt thereof are administered with a dry powder inhaler.
  • compositions administered with dry powder inhalers comprise one or more of nanoparticles, spray dried materials, engineered porous particles with low mass median diameter but a high geometric diameter, liposomes, and stealth (or PEGylated) liposomes.
  • compositions administered by dry powder inhalers administered in the methods disclosed herein comprise nanoparticle clusters that aggregate into micrometer sized particles at neutral or basic pH but dissociate into nanoparticles at the pH encountered in the lung.
  • the nanoparticle clusters comprise fumaryl diketopiperazine.
  • compositions administered with dry powder inhalers comprise lactose. In certain embodiments, compositions administered with dry powder inhalers do not comprise lactose. In certain embodiments, compositions administered with a dry powder inhaler have a MMAD between 2 and 4 ⁇ m, a GSD between 1.5 and 2.5 ⁇ m, and an RF ( ⁇ 5 ⁇ m) between 30% and 80%.
  • a dry powder inhaler used to administer an inhalation formulation in the methods disclosed herein comprises a pre-metered dose, such as Plastiape Monodose inhaler, which comprises a capsule pre-filled with a powder.
  • a dry powder inhaler used to administer an inhalation formulation in the methods disclosed herein has a device-metered system such as Twisthaler, sold by Schering Plough, which comprises a reservoir to store a powder and a twisting top to dispense each dose.
  • Twisthaler sold by Schering Plough
  • Inhalation formulations for administration with a dry powder inhaler may be prepared by blending cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium, with lactose, or spray drying cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium, or by pelletizing cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium, to form free-flowing spherical agglomerates.
  • cromolyn or a pharmaceutically acceptable salt thereof e.g., cromolyn sodium
  • lactose lactose
  • spray drying cromolyn or a pharmaceutically acceptable salt thereof e.g., cromolyn sodium
  • pelletizing cromolyn or a pharmaceutically acceptable salt thereof e.g., cromolyn sodium
  • compositions comprising cromolyn or a pharmaceutically acceptable salt thereof are administered with a metered dose inhaler.
  • a composition administered with a metered dose inhaler in the methods disclosed herein comprises one or more of nanoparticles, spray dried materials, engineered porous particles with low mass median diameter but a high geometric diameter, liposomes, and stealth (or PEGylated) liposomes.
  • compositions comprising cromolyn or a pharmaceutically acceptable salt thereof are administered with a thermal aerosol inhaler.
  • the aerosol in a thermal aerosol inhaler is generated by directly heating and vaporizing a thin solid film of the cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium, or by heating and vaporizing a solution of cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium in solvents such as propylene glycol and/or glycerol and water.
  • compositions comprising cromolyn or a pharmaceutically acceptable salt thereof are administered with an electrohydrodynamic-based solution misting inhaler.
  • the aerosol in the electrohydrodynamic-based solution-misting inhaler is generated by subjecting a solution of cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium, or a liposome or pegylated liposome comprising cromolyn or a pharmaceutically acceptable salt thereof, e.g., cromolyn sodium, to electrohydrodynamic forces through electrostatic energy.
  • Nebulizers are inhalation devices that comprise a micro-perforated membrane through which a liquid solution is converted through electrical or mechanical means into aerosol droplets suitable for inhalation. Nebulizers can deliver a large fraction of a loaded dose to a subject. In certain embodiments, the nebulizer also utilizes one or more actively or passively vibrating microperforated membranes. In certain embodiments, the nebulizer contains one or more oscillating membranes. In certain embodiments, the nebulizer contains a vibrating mesh or plate with multiple apertures and optionally a vibration generator with an aerosol mixing chamber. In some such embodiments, the mixing chamber functions to collect (or stage) the aerosol from the aerosol generator.
  • an inhalation valve is also used to allow an inflow of ambient air into the mixing chamber during an inhalation phase and is closed to prevent escape of the aerosol from the mixing chamber during an exhalation phase.
  • the exhalation valve is arranged at a mouthpiece which is removably mounted at the mixing chamber and through which the subject inhales the aerosol from the mixing chamber.
  • the nebulizer contains a pulsating membrane. In certain embodiments, the nebulizer is continuously operating.
  • the nebulizer contains a vibrating micro-perforated membrane of tapered nozzles that generates a plume of droplets without the need for compressed gas.
  • a solution in the micro-perforated membrane nebulizer is in contact with a membrane, the opposite side of which is open to the air.
  • the membrane is perforated by a large number of nozzle orifices of an atomizing head.
  • An aerosol is created when alternating acoustic pressure in the solution is built up in the vicinity of the membrane causing the fluid on the liquid side of the membrane to be emitted through the nozzles as uniformly sized droplets.
  • nebulizers use passive nozzle membranes and a separate piezoelectric transducer that stimulates the membrane.
  • some nebulizers employ an active nozzle membrane, which use the acoustic pressure in the nebulizer to generate very fine droplets of solution via the high frequency vibration of the nozzle membrane.
  • nebulizers contain a resonant system.
  • the membrane is driven by a frequency for which the amplitude of the vibrational movement at the center of the membrane is particularly large, resulting in a focused acoustic pressure in the vicinity of the nozzle; the resonant frequency may be about 100 kHz.
  • a flexible mounting is used to keep unwanted loss of vibrational energy to the mechanical surroundings of the atomizing head to a minimum.
  • the vibrating membrane of the nebulizer may be made stainless steel, or of a nickel-palladium alloy by electroforming.
  • a nebulizer may be adapted or adaptable to operate in conjunction with a unit dosage form, such as an ampule or vial, which contains a single dose of composition comprising cromolyn or a pharmaceutically-acceptable salt thereof for the treatment of chronic cough due to IPF.
  • the unit dosage form comprises a container that contains an inhalation formulation comprising the cromolyn or a pharmaceutically-acceptable salt thereof, such as cromolyn sodium.
  • the container is adapted to cooperate with the nebulizer device in such a way as to permit administration of the nominal dose of the inhalation formulation to a subject.
  • the nebulizer and the unit dosage form are configured so that they are useable together, but not with other devices or dosage forms.
  • the unit dosage form is configured such that it fits into a keyhole-like structure in the nebulizer, but will not operate with other nebulizer devices.
  • the nebulizer is configured such that it will accept and properly operate with the unit dosage form containing the cromolyn or a pharmaceutically-acceptable salt thereof, but not with other dosage forms.
  • nebulizers are available from: PARI (Germany) under the trade name eFlow®; Aerogen, Ltd. (Ireland) under the trade names AeroNeb® Go and AeroNeb® Pro, AeroNeb® Solo, and other nebulizers utilizing the OnQ® nebulizer technology; Respironics (Murrysville, Calif.) under the trade names I-Neb®; Omron (Bannockburn, Ill.) under the trade name Micro-Air®; Activaero (Germany) under the trade name Akita®, and AerovectRx (Atlanta, Ga.) under the trade name AerovectRx®.
  • the methods disclosed herein comprise administration to a subject a nominal dose of cromolyn or a pharmaceutically-acceptable salt thereof with a nebulizer, wherein administration of the nominal dose of the cromolyn or a pharmaceutically-acceptable salt thereof to the subject provides one or more of the following advantages: (1) an enhanced pharmacokinetic profile as compared to administration of an oral solution; (2) an enhanced therapeutic effect as compared to administration of an oral solution; (3) an enhanced lung deposition (deposited lung dose) as compared with some inhalation devices used with other cromolyn sodium compositions evidenced by scintigraphy or deconvolution, or derived from suitable in vitro indicators such as enhanced RD, RDDR, RF, and lower GSDs, as compared to administration with some inhalation devices used with other cromolyn sodium compositions; (4) reduced administration times, periods, and/or volumes as compared to administration with some other formulations and inhalation devices; (5) a reduction in adverse side effects associated with oral formulations of cromol
  • the DD expressed as the percentage of the nominal dose of cromolyn or a pharmaceutically-acceptable salt thereof administered with a nebulizer in the methods disclosed herein is at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, about 65%, about 70%, about 30% to about 90%, about 40% to about 80%, about 45% to about 75%, about 50% to about 70%, about 30% to about 75%, about 40% to about 70%, about 45% to about 60%, or about 60% to about 70%.
  • TOR is the speed at which the liquid containing cromolyn or a pharmaceutically-acceptable salt thereof is administered from the inhalation device.
  • administration of the cromolyn or a pharmaceutically-acceptable salt thereof with the nebulizer provides a TOR of at least about 2 times, 3 times or 4 times the TOR achievable with a conventional inhalation device, such as a nebulizer.
  • the TOR is at least about at least about 150 mg/min, at least about 200 mg/min, at least about 250 mg/min, at least 300 mg/min, at least 350 mg/min, at least 400 mg/min, at least 500 mg/min, or from 200 to about 700 mg/min.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, or about 55% to about 90%.
  • RF ⁇ 3.3 ⁇ m
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) of cromolyn sodium of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55% to about 90%, about 40% to about 50%
  • the solution comprises an osmotic agent comprising sodium chloride. In certain embodiments, the solution comprises an osmotic agent consisting of sodium chloride. In certain embodiments, the osmolality of the solution is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg
  • the osmolality of the solution is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the solution of the disclosure may exclude, or, may not comprise a surfactant. In certain embodiments, the solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • use of a nebulizer in the methods disclosed herein provides an aerosol that comprises particles having a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution that comprises particles having a surface tension in the range similar to that or water or higher.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution that comprises particles having a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution that comprises particles having a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF (1-5 ⁇ m) of cromolyn or a pharmaceutically-acceptable salt thereof of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, or about 55%
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF (1-5 ⁇ m) of cromolyn sodium of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, or about 55% to about 90%.
  • the solution comprises an osmotic agent comprising sodium chloride. In certain embodiments, the solution comprises an osmotic agent consisting of sodium chloride. In certain embodiments, the solution comprises an osmotic agent comprising sodium chloride. In certain embodiments, the solution comprises an osmotic agent consisting of sodium chloride.
  • the osmolality of the solution is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 130 mOsm/kg.
  • the osmolality of the solution is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the solution of the disclosure may exclude, or, may not comprise a surfactant. In certain embodiments, the solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • use of a nebulizer in the methods disclosed herein provides an aerosol that comprises particles having a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution that comprises particles having a surface tension in the range similar to that or water or higher.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution that comprises particles having a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution that comprises particles having a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 5 ⁇ m) of an cromolyn or a pharmaceutically-acceptable salt thereof of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55%
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 5 ⁇ m) of cromolyn sodium of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55% to about 90%, about 70% to about 80%
  • the solution comprises an osmotic agent comprising sodium chloride. In certain embodiments, the solution comprises an osmotic agent consisting of sodium chloride. In certain embodiments, the osmolality of the solution is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg
  • the osmolality of the solution is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the solution of the disclosure may exclude, or, may not comprise a surfactant. In certain embodiments, the solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • the aerosols provided by the present methods or nebulizer comprise particles having a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli.
  • the aerosols provided by the present methods or nebulizer comprise particles having surface tension in the range similar to that or water or higher.
  • the aerosols provided by the present methods or nebulizer comprise particles having a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • the aerosols provided by the present methods or nebulizer comprise particles having surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides a pharmaceutically acceptable solution, comprising from about 1% to about 10% by weight of cromolyn sodium an osmotic agent, wherein the osmotic agent consists of sodium chloride, wherein an aerosol created from the pharmaceutically acceptable solution is suitable for inhalation by a subject having chronic cough due to idiopathic pulmonary fibrosis.
  • the aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%.
  • the aerosol has a respirable fraction ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30% and a respirable fraction ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 75%.
  • the pharmaceutically acceptable solution comprises about 1%, or about 2%, or about 3%, or about 4%, or about 5%, or about 6%, or about 7%, or about 8%, or about 9%, or about 10% by weight of cromolyn sodium.
  • the osmostic agent comprises an ionic osmotic agent and excludes any non-ionic osmotic agent.
  • the osmotic agent consists of sodium chloride.
  • the osmolality of the solution is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 130 mOsm/kg.
  • the osmolality of the solution is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the pharmaceutically acceptable solution of the disclosure may exclude, or, may not comprise a surfactant. In certain embodiments, the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • PEG polyethylene
  • the pharmaceutically acceptable solution has a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli. In certain embodiments the pharmaceutically acceptable solution has a surface tension in the range similar to that or water or higher. the pharmaceutically acceptable solution has a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • the pharmaceutically acceptable solution has a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides any of the methods or pharmaceutically acceptable solutions disclosed herein wherein the pharmaceutically acceptable solution has an osmolality of less than about 250 mOsm/kg, or less than about 225 mOsm/kg, or less than about 200 mOsm/kg, or less than about 190 mOsm/kg, or less than about 180 mOsm/kg, or less than about 175 mOsm/kg, or less than about 170 mOsm/kg, or less than about 165 mOsm/kg, or less than about 160 mOsm/kg, or less than about 155 mOsm/kg, or less than about 150 mOsm/kg, or less than about 145 mOsm/kg, or less than about 140 mOsm/kg, or less than about 135 mOsm/kg, or less than about 130 mOsm/kg, or less than about 125 mOsm/kg, or less than about 120 mO
  • the pharmaceutically acceptable solution has an osmolality of between about 70 mOsm/kg and about 200 mOsm/kg, or between about 70 mOsm/kg and about 190 mOsm/kg, or between about 70 and about 180 mOsm/kg, or between about 70 mOsm/kg and about 170 mOsm/kg, or between about 70 mOsm/kg and about 160 mOsm/kg, or between about 70 mOsm/kg and about 150 mOsm/kg, or between about 70 mOsm/kg and about 140 mOsm/kg, or between about 80 mOsm/kg and about 200 mOsm/kg, or between about 80 mOsm/kg and about 190 mOsm/kg, or between about 90 mOsm/kg and about 180 mOsm/kg, or between about 90 mOsm/kg and about 175 mOsm/kg
  • the osmolality of the pharmaceutically acceptable solution is about 100 mOsm/kg, or about 110 mOsm/kg, or about 115 mOsm/kg, or about 120 mOsm/kg, or about 125 mOsm/kg, or about 130 mOsm/kg, or about 135 mOsm/kg, or about 140 mOsm/kg, or about 145 mOsm/kg, or about 150 mOsm/kg, or about 155 mOsm/kg, or about 160 mOsm/kg, or about 165 mOsm/kg, or about 170 mOsm/kg, or about 175 mOsm/kg, or about 180 mOsm/kg, or about 185 mOsm/kg, or about 190 mOsm/kg, or about 195 mOsm/kg, or about 200 mOsm/kg.
  • the disclosure provides any of the methods or pharmaceutically acceptable solutions disclosed herein wherein the pharmaceutically acceptable solution may exclude, or, may not comprise a surfactant. In certain embodiments, the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • surfactants that are excluded from the present pharmaceutically acceptable solution include any compound or agent that lowers the surface tension of a composition.
  • the disclosure provides any of the methods or pharmaceutically acceptable solutions disclosed herein wherein the pharmaceutically acceptable solution has a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli.
  • the pharmaceutically acceptable solution has a surface tension in the range similar to that or water or higher.
  • the pharmaceutically acceptable solution has a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • the pharmaceutically acceptable solution has a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides a pharmaceutically acceptable solution, comprising from about 2% to about 6% by weight of cromolyn sodium and an osmolarity adjusting agent consisting of sodium chloride, wherein an aerosol created from the pharmaceutically acceptable solution is suitable for inhalation by a subject in need thereof.
  • the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%.
  • the aerosol exhibits and RF ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%.
  • the pharmaceutically acceptable solution of the disclosure may exclude, or, may not comprise a surfactant. In certain embodiments, the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • PEG polyethylene
  • the pharmaceutically acceptable solution has a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli. In certain embodiments the pharmaceutically acceptable solution has a surface tension in the range similar to that or water or higher. the pharmaceutically acceptable solution has a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • the pharmaceutically acceptable solution has a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides a pharmaceutically acceptable aerosol, comprising droplets of a solution comprising from about 1% to about 10% by weight of cromolyn sodium and an osmolarity adjusting agent consisting of sodium chloride.
  • the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%.
  • the aerosol exhibits and RF ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%.
  • the osmolality of the solution is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 130 mOsm/kg.
  • the osmolality of the solution is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the pharmaceutically acceptable solution of the disclosure may exclude, or, may not comprise a surfactant. In certain embodiments, the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • PEG polyethylene
  • droplets of the pharmaceutically acceptable aerosols have a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension in the range similar to that or water or higher. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • droplets of the pharmaceutically acceptable aerosols have a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides a method of administering a therapeutically effective amount of cromolyn sodium to a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising from about 2% to about 6% by weight of cromolyn sodium and an osmotic agent consisting of sodium chloride, wherein the pharmaceutical composition is administered to the subject by inhalation in the form of an aerosol exhibiting an RF ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 60%.
  • the aerosol exhibits an RF ( 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%.
  • the aerosol exhibits an RF ( 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%.
  • the aerosol exhibits and RF ( 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%.
  • the osmolality of the pharmaceutical composition is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 130 mOsm/kg.
  • the osmolality of the pharmaceutical composition is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the pharmaceutically acceptable solution or composition of the disclosure may exclude, or, may not comprise a surfactant.
  • the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • Some examples of surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • PEG polyethylene glyco
  • droplets of the pharmaceutically acceptable aerosols have a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension in the range similar to that or water or higher. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • droplets of the pharmaceutically acceptable aerosols have a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides a dosage form comprising: (a) a pharmaceutical composition comprising from about 2% to about 6% by weight of cromolyn sodium, and an osmolarity adjusting agent consisting of sodium chloride; and (b) an inhalation device that forms an aerosol of the pharmaceutical composition, the aerosol exhibiting a respirable fraction of the pharmaceutical composition ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 60%.
  • the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%.
  • the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%.
  • RF ⁇ 3.3 ⁇ m
  • the aerosol exhibits and RF ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%.
  • the osmolality of the pharmaceutical composition is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 130 mOsm/kg.
  • the osmolality of the pharmaceutical composition is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the pharmaceutically acceptable dosage form of the disclosure may exclude, or, may not comprise a surfactant.
  • the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • PEG polyethylene glycol
  • droplets of the pharmaceutically acceptable aerosols have a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension in the range similar to that or water or higher. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • droplets of the pharmaceutically acceptable aerosols have a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • the disclosure provides a dosage form comprising: (a) a pharmaceutical composition comprising from about 2% to about 6% by weight of cromolyn sodium, and an osmolarity adjusting agent consisting of sodium chloride; and (b) a means for producing an aerosol of the pharmaceutical composition, the aerosol exhibiting a respirable fraction of the pharmaceutical composition ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 60%.
  • the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%.
  • the aerosol exhibits an RF ( ⁇ 3.3 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, or at least about 80%.
  • RF ⁇ 3.3 ⁇ m
  • the aerosol exhibits and RF ( ⁇ 5 ⁇ m) as measured by USP ⁇ 1601> of at least about 30%, or at least about 35%, or at least about 40%, or at least about 45%, or at least about 50%, or at least about 55%, or at least about 60%, or at least about 65%, or at least about 75%, or at least about 80%, or at least about 85%, or at least about 90%, or at least about 95%.
  • the osmolality of the pharmaceutical composition is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 130 mOsm/kg.
  • the osmolality of the pharmaceutical composition is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the pharmaceutically acceptable dosage form of the disclosure may exclude, or, may not comprise a surfactant.
  • the pharmaceutically acceptable solution of the disclosure may not comprise any dispersing agent, solubilizing agent, or spreading agent.
  • surfactants that are excluded from the present compositions and formulations include: PEG (polyethylene glycol) 400; Sodium lauryl sulfate sorbitan laurate, sorbitan palmitate, sorbitan stearate available under the tradename Span® (20-40-60 etc.); polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monopalmitate, polyoxyethylene (20) sorbitan monostearate available under the tradename Tween (polysorbates, 20-40-60 etc.); tyloxapol; propylene glycol; and Benzalkoniurn chloride, vitamin-TPGS and lecithins, (Exosurf®, GlaxoSmithKline), surfactant proteins.
  • PEG polyethylene glycol
  • droplets of the pharmaceutically acceptable aerosols have a surface tension suitable for deposition, penetration or retention of the composition primarily in the peripheral lung regions, including the bronchioles and alveoli. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension in the range similar to that or water or higher. In certain embodiments, droplets of the pharmaceutically acceptable aerosols have a surface tension of at least about 30 mN/m, or at least about 40 mN/m, or at least about 50 mN/m, or at least about 60 mN/m, or at least about 70 mN/m.
  • droplets of the pharmaceutically acceptable aerosols have a surface tension in the range of about 30 mN/m to about 75 mN/m, or about 50 mN/m to about 75 mN/m, or about 70 mN/m to about 75 mN/m.
  • use of a nebulizer in the methods disclosed herein provides a RDDR of at least about 2 times, at least about 3 times or at least about 4 times the RDDR achievable with a conventional inhalation device.
  • the RDDR is at least about 5 mg/min, at least about 10 mg/min, at least about 15 mg/min, at least about 20 mg/min, at least about 25 mg/min, at least about 30 mg/min, at least about 35 mg/min, at least about 40 mg/min, at least about 45 mg/min, at least about 50 mg/min, at least about 55 mg/min, or at least about 60 mg/min.
  • administration of cromolyn or a pharmaceutically-acceptable salt thereof with a nebulizer in the methods disclosed herein provides a GSD of emitted droplet size distribution of about 1.1 to about 2.1, about 1.2 to about 2.0, about 1.3 to about 1.9, less than about 2, at least about 1.4 to about 1.8, at least about 1.5 to about 1.7, about 1.4, about 1.5, about 1.6, or about 1.7.
  • administration of cromolyn or a pharmaceutically-acceptable salt thereof with a nebulizer in the methods disclosed herein provides a MMAD of droplet size of about 1 ⁇ m to about 5 ⁇ m, about 2 to about 4 ⁇ m, about 3 to about 4 ⁇ m, about 3.5 to about 4.5 ⁇ m, or about 3.5 ⁇ m.
  • administration of cromolyn or a pharmaceutically-acceptable salt thereof in the methods disclosed herein provides droplets having a particular combination of MMAD and GSD, for example: an MMAD of less than about 5 ⁇ m and a GSD of about 1.1 to about 2.1; an MMAD of less than about 4.5 ⁇ m and a GSD of about 1.1 to about 2.1; an MMAD of about 1 ⁇ m to about 5 ⁇ m and a GSD of about 1.1 to about 2.1; an MMAD of about 1.5 to about 4.5 ⁇ m and a GSD of about 1.1 to about 2.1; an MMAD of less than about 5 ⁇ m and a GSD of about 1.1 to about 2.0; an MMAD of less than about 4.5 ⁇ m and a GSD of about 1.1 to about 2.0; an MMAD of about 1 ⁇ m to about 5 ⁇ m and a GSD of about 1.1 to about 2.0; an MMAD of about 1.5 to about 4.5 ⁇ m and ⁇ m and a
  • the median particle size of cromolyn or a pharmaceutically-acceptable salt thereof aerosol administered with a nebulizer is between about 1 ⁇ m and about 6 ⁇ m, between about 2 ⁇ m and about 5 ⁇ m, between about 3 ⁇ m and about 5 ⁇ m, between about 3 ⁇ m and about 4 ⁇ m, about 1 ⁇ m, about 2 ⁇ m, about 3 ⁇ m, about 4 ⁇ m, about 5 ⁇ m, or about 6 ⁇ m.
  • the median particle size of cromolyn sodium aerosol administered with a nebulizer is between about 1 ⁇ m and about 6 ⁇ m, between about 2 ⁇ m and about 5 ⁇ m, between about 3 ⁇ m and about 5 ⁇ m, between about 3 ⁇ m and about 4 ⁇ m, about 1 ⁇ m, about 2 ⁇ m, about 3 ⁇ m, about 4 ⁇ m, about 5 ⁇ m, or about 6 ⁇ m.
  • formulations comprising from about 2% to about 10% by weight cromolyn sodium and an osmotic agent consisting of sodium chloride, wherein the formulation is stable when stored at 25° C. for at least 4 weeks, or at least 6 weeks, or at least 8 weeks, or at least 10 weeks, or at least 12 weeks, or at least 6 months, or at least 8 months, or at least 10 months, or at least 12 months, or at least 14 months, or at least 16 months, or at least 18 months, or at least 20 months, or at least 24 months.
  • the formulations remain clear solutions when stored at 25° C. for these same time periods.
  • the formulations exhibit less than 1% by weight total impurities when stored at 25° C.
  • the formulation comprises about 4% by weight of cromolyn sodium. In certain embodiments, the formulation comprises about 6% by weight of cromolyn sodium. In certain embodiments, the osmolality of the formulation is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and
  • the osmolality of the formulation is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • formulations comprising from about 2% to about 10% by weight cromolyn sodium and an osmotic agent consisting of sodium chloride, wherein the formulation is stable when stored at 40° C. for at least 4 weeks, or at least 6 weeks, or at least 8 weeks, or at least 10 weeks, or at least 12 weeks, or at least 6 months, or at least 8 months, or at least 10 months, or at least 12 months, or at least 14 months, or at least 16 months, or at least 18 months, or at least 20 months, or at least 24 months.
  • the formulations remain clear solutions when stored at 40° C. for these same time periods.
  • the formulations exhibit less than 1% by weight total impurities when stored at 40° C.
  • the formulation comprises about 4% by weight of cromolyn sodium. In certain embodiments, the formulation comprises about 6% by weight of cromolyn sodium In certain embodiments, the osmolality of the formulation is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about
  • the osmolality of the formulation is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • inhalation formulations are administered by an inhalation device, e.g., a nebulizer, to provide a systemically effective amount of cromolyn or a pharmaceutically-acceptable salt thereof for the treatment of chronic cough due to IPF.
  • the methods disclosed herein comprise administering a nominal dose of cromolyn or a pharmaceutically-acceptable salt thereof in an aqueous inhalation solution to the subject with an inhalation device, e.g., a nebulizer.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC(0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 100 ng*hr/mL, greater than about 110 ng*hr/mL, greater than about 120 ng*hr/mL, greater than about 130 ng*hr/mL, greater than about 140 ng*hr/mL, greater than about 150 ng*hr/mL, greater than about 160 ng*hr/mL, greater than about 170 ng*hr/mL, greater than about 180 ng*hr/mL, greater than about 190 ng*hr/mL, greater than about 200 ng*hr/mL, greater than about 225 ng*hr/mL, greater than about 250 ng*hr/mL, greater than about 275 ng*hr/mL, greater than about
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 100 ng*hr/mL, greater than about 110 ng*hr/mL, greater than about 120 ng*hr/mL, greater than about 130 ng*hr/mL, greater than about 140 ng*hr/mL, greater than about 150 ng*hr/mL, greater than about 160 ng*hr/mL, greater than about 170 ng*hr/mL, greater than about 180 ng*hr/mL, greater than about 190 ng*hr/mL, greater than about 200 ng*hr/mL, greater than about 225 ng*hr/mL, greater than about 250 ng*hr/mL, greater than about 275 ng*hr/mL, greater than about
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof of about 100 ng*hr/mL, about 110 ng*hr/mL, about 120 ng*hr/mL, about 130 ng*hr/mL, about 140 ng*hr/mL, about 150 ng*hr/mL, about 160 ng*hr/mL, about 170 ng*hr/mL, about 180 ng*hr/mL, about 190 ng*hr/mL, about 200 ng*hr/mL, about 225 ng*hr/mL, about 250 ng*hr/mL, ng*hr/mL, about 275 ng*hr/mL, about 300 ng*hr/mL, about 325 ng*hr/mL, about 325 ng*hr/mL
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof of about 100 ng*hr/mL, about 110 ng*hr/mL, about 120 ng*hr/mL, about 130 ng*hr/mL, about 140 ng*hr/mL, about 150 ng*hr/mL, about 160 ng*hr/mL, about 170 ng*hr/mL, about 180 ng*hr/mL, about 190 ng*hr/mL, about 200 ng*hr/mL, about 225 ng*hr/mL, about 250 ng*hr/mL, ng*hr/mL, about 275 ng*hr/mL, about 300 ng*hr/mL, about 325 ng*hr/mL, about 325 ng*hr/mL
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 100 ng*hr/mL, greater than about 110 ng*hr/mL, greater than about 120 ng*hr/mL, greater than about 130 ng*hr/mL, greater than about 140 ng*hr/mL, greater than about 150 ng*hr/mL, greater than about 160 ng*hr/mL, greater than about 170 ng*hr/mL, greater than about 180 ng*hr/mL, greater than about 190 ng*hr/mL, greater than about 200 ng*hr/mL, greater than about 225 ng*hr/mL, greater than about 250 ng*hr/mL, greater than about 275 ng*hr/mL, greater than about 300 ng*hr/mL
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 100 ng*hr/mL, greater than about 110 ng*hr/mL, greater than about 120 ng*hr/mL, greater than about 130 ng*hr/mL, greater than about 140 ng*hr/mL, greater than about 150 ng*hr/mL, greater than about 160 ng*hr/mL, greater than about 170 ng*hr/mL, greater than about 180 ng*hr/mL, greater than about 190 ng*hr/mL, greater than about 200 ng*hr/mL, greater than about 225 ng*hr/mL, greater than about 250 ng*hr/mL, greater than about 275 ng*hr/mL, greater than about 300 ng*hr/mL
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 100 ng*hr/mL, about 110 ng*hr/mL, about 120 ng*hr/mL, about 130 ng*hr/mL, about 140 ng*hr/mL, about 150 ng*hr/mL, about 160 ng*hr/mL, about 170 ng*hr/mL, about 180 ng*hr/mL, about 190 ng*hr/mL, about 200 ng*hr/mL, about 225 ng*hr/mL, about 250 ng*hr/mL, ng*hr/mL, about 275 ng*hr/mL, about 300 ng*hr/mL, about 325 ng*hr/mL, about 350 ng*hr/mL
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 100 ng*hr/mL, about 110 ng*hr/mL, about 120 ng*hr/mL, about 130 ng*hr/mL, about 140 ng*hr/mL, about 150 ng*hr/mL, about 160 ng*hr/mL, about 170 ng*hr/mL, about 180 ng*hr/mL, about 190 ng*hr/mL, about 200 ng*hr/mL, about 225 ng*hr/mL, about 250 ng*hr/mL, ng*hr/mL, about 275 ng*hr/mL, about 300 ng*hr/mL, about 325 ng*hr/mL, about 350 ng*hr/mL
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/m
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/m
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn or a pharmaceutically-acceptable salt thereof of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, about 260 ng/mL, about 270 ng/mL,
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn or a pharmaceutically-acceptable salt thereof of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, about 260 ng/mL, about 270 ng/mL,
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn sodium greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/mL, greater than about 230 ng
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn sodium greater than about 40 ng/mL, greater than about 50 ng/mL, greater than about 60 ng/mL, greater than about 70 ng/mL, greater than about 80 ng/mL, greater than about 90 ng/mL, greater than about 100 ng/mL, greater than about 110 ng/mL, greater than about 120 ng/mL, greater than about 130 ng/mL, greater than about 140 ng/mL, greater than about 150 ng/mL, greater than about 160 ng/mL, greater than about 170 ng/mL, greater than about 180 ng/mL, greater than about 190 ng/mL, greater than about 200 ng/mL, greater than about 210 ng/mL, greater than about 220 ng/mL, greater than about 230 ng
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn sodium of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, about 260 ng/mL, about 270 ng/mL, about 280 ng/mL,
  • an inhalation formulation administered with an inhalation device produces in a subject a Cmax of cromolyn sodium of about 50 mg/mL, about 60 ng/mL, about 70 ng/mL, about 80 ng/mL, about 90 ng/mL, about 100 ng/mL, about 110 ng/mL, about 120 ng/mL, about 130 ng/mL, about 140 ng/mL, about 150 ng/mL, about 160 ng/mL, about 170 ng/mL, about 180 ng/mL, about 190 ng/mL, about 200 ng/mL, about 210 ng/mL, about 220 ng/mL, about 230 ng/mL, about 240 ng/mL, about 250 ng/mL, about 260 ng/mL, about 270 ng/mL, about 280 ng/mL,
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 120 ng*hr/mL and/or an average Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 55 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 120 ng*hr/mL and/or a Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 55 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an e.g., a nebulizer, produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 200 ng*hr/mL and an average Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 80 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 200 ng*hr/mL and a Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 80 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 330 ng*hr/mL and an average Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 150 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 330 ng*hr/mL and a Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 150 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 525 ng*hr/mL and an average Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 230 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 525 ng*hr/mL and a Cmax of the cromolyn or a pharmaceutically-acceptable salt thereof greater than about 230 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 120 ng*hr/mL and/or an average Cmax of cromolyn sodium greater than about 55 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 120 ng*hr/mL and/or a Cmax of cromolyn sodium greater than about 55 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 120 ng*hr/mL and an average Cmax of cromolyn sodium greater than about 55 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 120 ng*hr/mL and a Cmax of cromolyn sodium greater than about 55 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 200 ng*hr/mL and an average Cmax of cromolyn sodium greater than about 80 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 200 ng*hr/mL and a Cmax of cromolyn sodium greater than about 80 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 330 ng*hr/mL and an average Cmax of cromolyn sodium greater than about 150 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 330 ng*hr/mL and a Cmax of cromolyn sodium greater than about 150 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 525 ng*hr/mL and an average Cmax of cromolyn sodium greater than about 230 ng/mL.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 525 ng*hr/mL and a Cmax of cromolyn sodium greater than about 230 ng/mL.
  • the administration of a formulation comprising about 40 mg of cromolyn sodium, or a pharmaceutically acceptable salt thereof, to a subject by means of an inhalation device affords a Cmax or average Cmax of cromolyn sodium in the subject of from about from 30 ng/mL to about 120 ng/mL, or from about 40 ng/mL to about 120 ng/mL, or from about 40 ng/mL to about 110 ng/mL.
  • the administration of a formulation comprising about 40 mg of cromolyn sodium, or a pharmaceutically acceptable salt thereof, to a subject by means of an inhalation device affords an AUC (0- ⁇ ) of cromolyn sodium in the subject of between about 100 ng*hr/mL and about 350 ng*hr/mL, or between about 100 ng*hr/mL and about 325 ng*hr/mL, or between about 115 ng*hr/mL and about 325 ng*hr/mL, or between about 120 ng*hr/mL and about 320 ng*hr/mL, or between about 125 ng*hr/mL and about 300 ng*hr/mL.
  • the formulation comprises between 1% and 10% by weight cromolyn sodium, or between about 4% by weight and 6% by weight cromolyn sodium. In certain embodiments, the formulation comprises 4% by weight cromolyn sodium. In certain embodiments, the formulation comprises 6% by weight cromolyn sodium.
  • use of a nebulizer to administer the formulation provides an aerosol of the formulation comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 5 ⁇ m) of an cromolyn or a pharmaceutically-acceptable salt thereof of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55% to about
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 5 ⁇ m) of cromolyn sodium of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55% to about 90%, about 70% to about about
  • the formulation comprises an osmotic agent comprising sodium chloride. In certain embodiments, the formulation comprises an osmotic agent consisting of sodium chloride. In certain embodiments, the osmolality of the formulation is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mO
  • the osmolality of the formulation is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • the administration of a formulation comprising about 60 mg of cromolyn sodium, or a pharmaceutically acceptable salt thereof, to a subject by means of an inhalation device affords a Cmax or average Cmax of cromolyn sodium in the subject of from about from 50 ng/mL to about 175 ng/mL, or from about 60 ng/mL to about 175 ng/mL, or from about 60 ng/mL to about 170 ng/mL, or from about 60 ng/mL to about 165 ng/mL, or from about 70 ng/mL to about 165 ng/mL.
  • the administration of a formulation comprising about 60 mg of cromolyn sodium, or a pharmaceutically acceptable salt thereof, to a subject by means of an inhalation device affords an AUC(0- ⁇ ) of cromolyn sodium in the subject of between about 200 ng*hr/mL and about 600 ng*hr/mL, or between about 200 ng*hr/mL and about 575 ng*hr/mL, or between about 200 ng*hr/mL and about 550 ng*hr/mL, or between about 200 ng*hr/mL and about 525 ng*hr/mL, or between about 210 ng*hr/mL and about 525 ng*hr/mL, or between about 215 ng*hr/mL and about 515 ng*hr/mL, or between about 175 ng*hr/mL and about 500 ng*hr/mL, or between about 195 ng*hr/mL and about
  • the formulation comprises between 1% and 10% by weight cromolyn sodium, or between about 4% by weight and 6% by weight cromolyn sodium. In certain embodiments, the formulation comprises 4% by weight cromolyn sodium. In certain embodiments, the formulation comprises 6% by weight cromolyn sodium.
  • use of a nebulizer to administer the formulation provides an aerosol of the formulation comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 5 ⁇ m) of an cromolyn or a pharmaceutically-acceptable salt thereof of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55% to about
  • use of a nebulizer in the methods disclosed herein provides an aerosol of a solution comprising cromolyn or a pharmaceutically-acceptable salt thereof, wherein the aerosol exhibits an RF ( ⁇ 5 ⁇ m) of cromolyn sodium of at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, about 20% to about 95%, about 35% to about 90%, or about 40% to about 80%, about 40% to about 90%, about 40% to about 95%, about 45% to about 90%, about 45% to about 95%, about 50% to about 90%, about 65% to about 90%, about 60% to about 95%, about 65% to about 95%, about 70% to about 90%, about 55% to about 90%, about 70% to about about
  • the formulation comprises an osmotic agent comprising sodium chloride. In certain embodiments, the formulation comprises an osmotic agent consisting of sodium chloride. In certain embodiments, the osmolality of the formulation is between about 100 mOsm/kg and about 175 mOsm/kg, or between about 100 mOsm/kg and about 170 mOsm/kg, or between about 100 mOsm/kg and about 165 mOsm/kg, or between about 100 mOsm/kg and about 160 mOsm/kg, or between about 100 mOsm/kg and about 150 mOsm/kg, or between about about 110 mOsm/kg and about 150 mOsm/kg, or between about 110 mOsm/kg and about 140 mOsm/kg, or between about 115 mOsm/kg and about 140 mOsm/kg, or between about 120 mOsm/kg and about 140 mO
  • the osmolality of the formulation is about 120 mOsm/kg, about 125 mOsm/kg, about 130 mOsm/kg, about 135 mOsm/kg, about 140 mOsm/kg, about 145 mOsm/kg, or about 150 mOsm/kg.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 330 ng*hr/mL and an average Cmax of cromolyn sodium of about 150 ng/mL when a nominal dose of 40 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 330 ng*hr/mL and a Cmax of cromolyn sodium of about 150 ng/mL when a nominal dose of 40 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 525 ng*hr/mL and an average Cmax of cromolyn sodium of about 230 ng/mL when a nominal dose of 80 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 525 ng*hr/mL and a Cmax of cromolyn sodium of about 230 ng/mL when a nominal dose of 80 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 180 ng*hr/mL to about 220 ng*hr/mL and an average Cmax of cromolyn sodium of about 70 ng/mL to about 90 ng/mL when a nominal dose of 40 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 180 ng*hr/mL to about 220 ng*hr/mL and a Cmax of cromolyn sodium of about 70 ng/mL to about 90 ng/mL when a nominal dose of 40 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 300 ng*hr/mL to about 360 ng*hr/mL and an average Cmax of cromolyn sodium of about 135 ng/mL to about 165 ng/mL when a nominal dose of 40 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 300 ng*hr/mL to about 360 ng*hr/mL and a Cmax of cromolyn sodium of about 135 ng/mL to about 165 ng/mL when a nominal dose of 40 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 475 ng*hr/mL to about 575 ng*hr/mL and an average Cmax of cromolyn sodium of about 200 ng/mL to about 260 ng/mL when a nominal dose of 80 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 475 ng*hr/mL to about 575 ng*hr/mL and a Cmax of cromolyn sodium of about 200 ng/mL to about 260 ng/mL when a nominal dose of 80 mg of cromolyn sodium is administered with the inhalation device.
  • an inhalation formulation administered with an inhalation device provides a lung deposition (deposited lung dose) comprising cromolyn or pharmaceutically acceptable salt thereof of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, about 20% to about 40%, about 25% to about 35%, about 25% to about 30%, about 25% to about 75%, about 30% to about 50%, about 35% to about 90%, about 40% to about 80%, about 40% to about 60%, about 50% to about 60%, about 50% to about 70%, or about 60% to about 75% based on the nominal dose of the cromolyn or a pharmaceutically-acceptable salt thereof.
  • a lung deposition deposited lung dose
  • cromolyn or pharmaceutically acceptable salt thereof of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least
  • an inhalation formulation administered with an inhalation device provides cromolyn sodium deposition (deposited lung dose) of at least about 15%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, about 20% to about 40%, about 25% to about 35%, about 25% to about 30%, about 25% to about 75%, about 30% to about 50%, about 35% to about 90%, about 40% to about 80%, about 40% to about 60%, about 50% to about 60%, about 50% to about 70%, or about 60% to about 75% based on the nominal dose of the cromolyn sodium.
  • cromolyn sodium deposition deposited lung dose
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • a lung deposition deposited lung dose
  • cromolyn or a pharmaceutically-acceptable salt thereof of about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75% about 80%, about 85%, about 90%, about 95%, or about 100% based on the nominal dose of the cromolyn or a pharmaceutically-acceptable salt thereof.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • cromolyn sodium lung deposition deposited lung dose of about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75% about 80%, about 85%, about 90%, about 95%, or about 100% based on the nominal dose of the cromolyn sodium.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • a lung deposition deposited lung dose
  • cromolyn or a pharmaceutically-acceptable salt thereof of greater than about 0.5 mg, greater than about 1 mg, greater than about 1.5 mg, greater than about 2 mg, greater than about 2.5 mg, greater than about 3 mg, greater than about 3.5 mg, greater than about 4 mg, greater than about 5 mg, greater than about 6 mg, greater than about 7 mg, greater than about 8 mg, greater than about 9 mg, greater than about 10 mg, greater than about 11 mg, greater than about 12 mg, greater than about 13 mg, greater than about 14 mg, or greater than about 15 mg.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • a lung deposition comprising cromolyn or a pharmaceutically-acceptable salt thereof of about 0.5 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg.
  • an inhalation formulation administered with an inhalation device provides cromolyn sodium lung deposition (deposited lung dose) of greater than about 0.5 mg, greater than about 1 mg, greater than about 1.5 mg, greater than about 2 mg, greater than about 2.5 mg, greater than about 3 mg, greater than about 3.5 mg, greater than about 4 mg, greater than about 5 mg, greater than about 6 mg, greater than about 7 mg, greater than about 8 mg, greater than about 9 mg, greater than about 10 mg, greater than about 11 mg, greater than about 12 mg, greater than about 13 mg, greater than about 14 mg, or greater than about 15 mg.
  • cromolyn sodium lung deposition deposited lung dose
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • cromolyn sodium lung deposition deposited lung dose of about 0.5 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 5.0 mg, about 6.0 mg, about 7.0 mg, about 8.0 mg, about 9.0 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, or about 15 mg.
  • an inhalation formulation containing cromolyn or a pharmaceutically-acceptable salt thereof is administered with an inhalation device, e.g., a nebulizer, at an administration of less than about 1 mg/dose, about 1 mg/dose to about 100 mg/dose, about 5 mg/dose to about 80 mg/dose, about 20 mg/dose to about 60 mg/dose, about 30 mg/dose to about 50 mg/dose, or greater than 100 mg/dose.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn sodium is administered with an inhalation device, e.g., a nebulizer, at an administration of less than about 1 mg/dose, about 1 mg/dose to about 100 mg/dose, about 5 mg/dose to about 80 mg/dose, about 20 mg/dose to about 60 mg/dose, about 30 mg/dose to about 50 mg/dose, or greater than 100 mg/dose.
  • an inhalation device e.g., a nebulizer
  • cromolyn or a pharmaceutically-acceptable salt thereof is administered in an inhalation formulation with an inhalation device, e.g., a nebulizer, in about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg doses, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about
  • cromolyn sodium is administered in an inhalation formulation with an inhalation device, e.g., a nebulizer, in about 1 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg doses, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 500 mg, about 550 mg, about 600 mg, about 650 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, or about 1000 mg doses
  • an inhalation device e.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer provides a bioavailability of cromolyn or a pharmaceutically-acceptable salt thereof of greater than about 5%, greater than about 6%, greater than about 7%, greater than about 8%, greater than about 9%, greater than about 10%, greater than about 11%, greater than about 12%, greater than about 13%, greater than about 14%, greater than about 15%, greater than about 16%, greater than about 17%, greater than about 18%, greater than about 19%, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45%, greater than about 50%, greater than about 55%, or greater than about 60% of the nominal dose.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer, in the methods disclosed herein provides a bioavailability of cromolyn or a pharmaceutically-acceptable salt thereof of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, or about 60% of the nominal dose.
  • a bioavailability of cromolyn or a pharmaceutically-acceptable salt thereof of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer provides a bioavailability of cromolyn sodium of greater than about 5%, greater than about 6%, greater than about 7%, greater than about 8%, greater than about 9%, greater than about 10%, greater than about 11%, greater than about 12%, greater than about 13%, greater than about 14%, greater than about 15%, greater than about 16%, greater than about 17%, greater than about 18%, greater than about 19%, greater than about 20%, greater than about 25%, greater than about 30%, greater than about 35%, greater than about 40%, greater than about 45% or greater than about 50% of the nominal dose.
  • an aqueous inhalation formulation administered with an inhalation device e.g., a nebulizer, in the methods disclosed herein provides a bioavailability of cromolyn sodium of about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 11%, about 12%, about 13%, about 14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% of the nominal dose.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, provides a bioavailability of cromolyn sodium greater than about 5% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 200 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, provides a bioavailability of cromolyn sodium greater than about 5% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 200 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, provides a bioavailability of cromolyn sodium greater than about 5% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 330 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, provides a bioavailability of cromolyn sodium greater than about 5% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 330 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 80 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, provides a bioavailability of cromolyn sodium greater than about 5% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 525 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 80 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, provides a bioavailability of cromolyn sodium greater than about 5% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 525 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device has an RF ( ⁇ 3.3 ⁇ m) of at least about 30% and produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 120 ng*hr/mL.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device has an RF ( ⁇ 3.3 ⁇ m) of at least about 30% and produces in a subject an AUC (0- ⁇ ) of cromolyn or a pharmaceutically-acceptable salt thereof greater than about 200 ng*hr/mL.
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, has an RF ( ⁇ 3.3 ⁇ m) of at least about 30% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 200 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, has an RF ( ⁇ 3.3 ⁇ m) of at least about 30% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 200 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, has an RF ( ⁇ 3.3 ⁇ m) of at least about 40% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 330 ng*hr/mL.
  • an inhalation formulation comprising 40 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, has an RF ( ⁇ 3.3 ⁇ m) of at least about 40% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 330 ng*hr/mL.
  • an inhalation formulation comprising 80 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, has an RF ( ⁇ 3.3 ⁇ m) of at least about 40% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 525 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation comprising 80 mg cromolyn sodium administered with an inhalation device, e.g., a nebulizer, has an RF ( ⁇ 3.3 ⁇ m) of at least about 40% and produces in a subject an AUC (0- ⁇ ) of cromolyn sodium greater than about 525 ng*hr/mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 8.5 ng*hr/mL per mg of cromolyn sodium, and an average Cmax of cromolyn sodium of about 3.9 ng/mL per mg of cromolyn sodium when a nominal dose of 40 mg cromolyn sodium is administered to the subject with an inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 8.5 ng*hr/mL per mg of cromolyn sodium, and an average Cmax of cromolyn sodium of about 1.9 ng/mL per mg of cromolyn sodium when a nominal dose of 40 mg cromolyn sodium is administered to the subject with an inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 9 ng*hr/mL and a Cmax of cromolyn sodium of about 2.6 ng/mL per mg of cromolyn sodium when a nominal dose of 60 mg of cromolyn sodium administered to the subject with the inhalation device.
  • an inhalation formulation administered with an inhalation device produces in a subject an AUC (0- ⁇ ) of cromolyn sodium of about 6.6 ng*hr/mL and an average Cmax of cromolyn sodium of about 2.95 ng/mL per mg of cromolyn sodium when a nominal dose of 80 mg of cromolyn sodium is administered to the subject with the inhalation device.
  • an inhalation formulation containing cromolyn or a pharmaceutically-acceptable salt thereof such as cromolyn sodium is administered with an inhalation device, e.g., a nebulizer, at a fill volume of less than about 0.25 mL, less than about 0.5 mL, at least about 0.5 mL to about 1.5 mL, at least about 0.5 mL to about 1.8 mL, at least about 1.5 mL, or at least about 2.0 mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation is administered with an inhalation device, e.g., a nebulizer, at a fill volume about 0.1 mL to about 5.0 mL, about 0.25 mL to about 2.0 mL, about 0.5 mL to about 1.8 mL, about 0.5 mL to about 2 mL, about 0.5 mL to about 1.5 mL, about 0.5 mL to about 1.0 mL, about 0.5 mL or less, about 1 mL or less, about 1.5 mL or less, about 2.0 mL or less, about 2.5 mL or less, about 3.0 mL or less, about 3.5 mL or less, about 4.0 mL or less, about 4.5 mL or less, or about 5.0 mL or less.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation is administered with an inhalation device, e.g., a nebulizer, at a fill volume of about 0.5 mL, about 1.0 mL, about 1.5 mL, about 1.8 mL, about 2.0 mL, about 2.5 mL, about 3.0 mL, about 3.5 mL, about 4.0 mL, about 4.5 mL, or about 5.0 mL.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation is administered with an inhalation device, e.g., a nebulizer, which provides for a residual volume of cromolyn or a pharmaceutically-acceptable salt thereof after administration of the cromolyn or a pharmaceutically-acceptable salt thereof of less than about 10%, less than about 5%, or less than about 3% of the nominal dose.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn or a pharmaceutically-acceptable salt thereof is administered with an inhalation device, e.g., a nebulizer, wherein the concentration of the cromolyn or a pharmaceutically-acceptable salt thereof is greater than about 1% by weight, greater than about 2% by weight, greater than about 3% by weight, greater than about 4% by weight, greater than about 5% by weight, greater than about 6% by weight, greater than about 7% by weight, greater than about 8% by weight, greater than about 9% by weight, or greater than about 10% by weight.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn or a pharmaceutically-acceptable salt thereof is administered with an inhalation device, e.g., a nebulizer, wherein the concentration of the cromolyn or a pharmaceutically-acceptable salt thereof is from about 1% by weight to about 10% by weight, from about 2% by weight to about 8% by weight, from about 2% by weight to about 6% by weight, or from about 3% by weight to about 5% by weight.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn or a pharmaceutically-acceptable salt thereof is administered with an inhalation device, e.g., a nebulizer, wherein the concentration of the cromolyn or a pharmaceutically-acceptable salt thereof is about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, or about 10% by weight.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn sodium is administered with an inhalation device, e.g., a nebulizer, wherein the concentration of the cromolyn sodium is greater than about 1% by weight, greater than about 2% by weight, greater than about 3% by weight, greater than about 4% by weight, greater than about 5% by weight, greater than about 6% by weight, greater than about 7% by weight, greater than about 8% by weight, greater than about 9% by weight, or greater than about 10% by weight.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn sodium is administered with an inhalation device, e.g., a nebulizer, wherein the concentration of the cromolyn sodium is from about 1% by weight to about 10% by weight, from about 2% by weight to about 8% by weight, from about 2% by weight to about 6% by weight, or from about 3% by weight to about 5% by weight.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn sodium is administered with an inhalation device, e.g., a nebulizer, wherein the concentration of the cromolyn sodium is about 1% by weight, about 2% by weight, about 3% by weight, about 4% by weight, about 5% by weight, about 6% by weight, about 7% by weight, about 8% by weight, about 9% by weight, or about 10% by weight.
  • an inhalation device e.g., a nebulizer
  • an inhalation formulation containing cromolyn or a pharmaceutically-acceptable salt thereof is administered with an inhalation device, e.g., a nebulizer, in about 0.25 to about 10 minutes, about 0.50 to about 8 minutes, less than about 8 minutes, less than about 7 minutes, less than about 6 minutes, less than about 5 minutes, less than about 4 minutes, less than about 3 minutes, less than about 2 minutes, less than about 1.8 minutes, less than about 1.5 minutes, or less than 1 minute.
  • the inhalation formulation is administered in about 3 minutes or less.
  • the inhalation formulation is administered in about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, about 8 minutes, about 9 minutes, or about 10 minutes.
  • administration of cromolyn or a pharmaceutically-acceptable salt thereof with a nebulizer provides at least about a 1.5-fold, at least about a 1.8-fold, at least about a two-fold, at least about a three-fold, at least about a four-fold, or at least about a five-fold increase in one or more of AUClast, AUC (0- ⁇ ) , or C max as compared to the same or lower nominal dose of the cromolyn or a pharmaceutically-acceptable salt thereof administered with a conventional inhalation device or an oral formulation, e.g., a liquid oral formulation, tablet, or capsule.
  • inhalation formulations administered with a nebulizer are substantially free of a preservative, such as benzyl alcohol.
  • inhalation formulations administered with a nebulizer further comprise at least one excipient.
  • the excipient is selected from the group consisting of stabilizers and antioxidants (such as citric acid, ascorbic acid, ethylenediamine tetra acetic acid (EDTA), sodium metabisulfite, or a salt of any thereof), an osmolarity adjusting agent (such as sodium chloride, mannitol, or sorbitol), a surfactant (such as polysorbate 80, vitamin E, tocopherol polyethylene glycol, and Tyloxapol), or a pH buffer.
  • stabilizers and antioxidants such as citric acid, ascorbic acid, ethylenediamine tetra acetic acid (EDTA), sodium metabisulfite, or a salt of any thereof
  • an osmolarity adjusting agent such as sodium chloride, mannitol, or sorbitol
  • a surfactant such as polysorbate 80, vitamin E, tocopherol polyethylene glycol, and Tyloxapol
  • inhalation formulations administered with an inhalation device are hypotonic. In certain embodiments of the methods disclosed herein, inhalation formulations administered with an inhalation device, e.g., a nebulizer, are sub-isotonic. In certain embodiments of the methods disclosed herein, inhalation formulations administered with an inhalation device, e.g., a nebulizer, have an osmolality greater than about 70 mOsm/kg.
  • inhalation formulations administered with an inhalation device e.g., nebulizer
  • inhalation formulations administered with an inhalation device e.g., nebulizer
  • the formulations comprising from about 2% to about 10% by weight of cromolyn sodium and an osmotic agent consisting of sodium chloride, are administered to a subject in need thereof in combination with an additional agent used to treat IPF.
  • the additional agent is selected from pirfenidone, an inhibitor of platelet-derived growth factor receptor (PDGFR) ⁇ , platelet-derived growth factor receptor (PDGFR) ⁇ , an inhibitor of fibroblast growth factor receptor (FGFR) 1-3, an inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, and an inhibitor of Fms-like tyrosine kinase-3 (FLT3).
  • the additional agent is pirfenadone or nintedanib esylate. In certain embodiments, the additional agent is pifenadone. In certain embodiments, the additional agent is nintedanib esylate.
  • a formulation comprising from about 2% to about 10% by weight of cromolyn sodium and an osmotic agent consisting of sodium chloride
  • an additional agent is selected from pirfenidone, an inhibitor of platelet-derived growth factor receptor (PDGFR) ⁇ , platelet-derived growth factor receptor (PDGFR) ⁇ , an inhibitor of fibroblast growth factor receptor (FGFR) 1-3, an inhibitor of vascular endothelial growth factor receptor (VEGFR) 1-3, and an inhibitor of Fms-like tyrosine kinase-3 (FLT3).
  • PDGFR platelet-derived growth factor receptor
  • PDGFR platelet-derived growth factor receptor
  • FGFR fibroblast growth factor receptor
  • VEGFR vascular endothelial growth factor receptor
  • FLT3 Fms-like tyrosine kinase-3
  • the additional agent is pirfenadone or nintedanib esylate. In certain embodiments, the additional agent is pifenadone. In certain embodiments, the additional agent is nintedanib esylate.
  • one or more different formulations of cromolyn or a pharmaceutically-acceptable salt thereof are co-administered by different routes of administration to provide systemically effective amounts of the cromolyn or a pharmaceutically-acceptable salt thereof.
  • a composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium is administered with a dry powder inhaler and a different composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium, is co-administered in a liquid oral formulation to treat chronic cough due to IPF.
  • a composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium is administered with a metered dose inhaler and a different composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium, is co-administered in a liquid oral formulation to treat chronic cough due to IPF.
  • a composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium is administered with a dry powder inhaler and a different composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium, is co-administered with a metered dose inhaler to treat chronic cough due to IPF.
  • a composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium is administered with a dry powder inhaler and a different composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium, is co-administered with a metered dose inhaler to treat chronic cough due to IPF.
  • a composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium is administered with a nebulizer and a different composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium, is co-administered in a liquid oral formulation to treat chronic cough due to IPF.
  • a composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium is administered with a jet nebulizer and a different composition comprising cromolyn or a pharmaceutically-acceptable salt thereof, e.g., cromolyn sodium, is co-administered in a liquid oral formulation to treat chronic cough due to IPF.
  • the term “about” is used synonymously with the term “approximately.”
  • the use of the term “about” with regard to a certain therapeutically effective pharmaceutical dose indicates that values in a range spanning a cited value, e.g., plus or minus up to 10% of a cited value, are also effective and safe.
  • the phrase “consisting essentially of” is a transitional phrase used in a claim to indicate that the following list of ingredients, parts or process steps must be present in the claimed composition, machine or process, but that the claim is open to unlisted ingredients, parts or process steps that do not materially affect the basic and novel properties of the invention.
  • Nominal dose refers to the loaded dose, which is the amount of active pharmaceutical ingredient (API) in an inhalation device prior to administration to the subject.
  • the volume of solution containing the nominal dose is referred to as the “fill volume.”
  • AUC last refers to the area under the curve from time zero to time of last measurable concentration of active pharmaceutical ingredient (API).
  • AUC lastHEN refers to the area under a blood plasma concentration curve up to the last time point for the nominal dose of active pharmaceutical ingredient (API) administered with a nebulizer.
  • AUC lastConv refers to the area under a blood plasma concentration curve up to the last time point for a nominal dose of active pharmaceutical ingredient (API) administered with a conventional inhalation device.
  • AUC (0- ⁇ ) refers to the total area under a blood plasma concentration curve for an active pharmaceutical ingredient (API).
  • AUC (0- ⁇ )HEN refers to the total area under a blood plasma concentration curve for a nominal dose of active pharmaceutical ingredient (API) administered with a nebulizer.
  • AUC (0- ⁇ )CONV refers to the total area under a blood plasma concentration curve for a nominal dose of active pharmaceutical ingredient (API) administered with a conventional inhalation device.
  • the AUC (0- ⁇ ) of an API can be determined by methods known to those of skill in the art.
  • the AUC (0- ⁇ ) of an API can be determined by collecting blood samples from a subject at various time points after administration of an API to the subject, separating plasma from the blood samples, extracting the API from the separated plasma samples, e.g., by solid-phase extraction, quantifying the amount of the API extracted from each sample of separated plasma, e.g., by liquid chromatography-tandem mass spectrometry (LC-MS/MS), plotting the concentration of API in each sample versus the time of collection after administration, and calculating the area under the curve.
  • LC-MS/MS liquid chromatography-tandem mass spectrometry
  • “Substantially the same nominal dose” as used herein means that a first nominal dose of an active pharmaceutical ingredient (API) contains approximately the same number of millimoles of the cromolyn or a pharmaceutically-acceptable salt thereof as a second nominal dose of the cromolyn or a pharmaceutically-acceptable salt thereof.
  • API active pharmaceutical ingredient
  • Bioavailability refers to the amount of unchanged API that reaches the systemic circulation, expressed as a percentage of the dosage of the API that is administered to a subject. By definition, the bioavailability of an intravenous solution containing the active pharmaceutical ingredient (API) is 100%. The bioavailability of an API can be determined by methods known to those of skill in the art.
  • the bioavailability of an API can be determined by collecting urine samples from a subject at various time points following administration of the API to the subject, extracting the API from the urine samples, e.g., by solid-phase extraction, quantifying the amount of the API in each urine sample, adjusting the amount of API collected from the urine by a factor based on the amount of API reaching systemic circulation that is excreted in the urine, and calculating the percentage of the API administered to the subject that reaches the systemic circulation of the subject.
  • the bioavailability of cromolyn sodium can be determined as described in Walker et al., 24 J. Pharm. Pharmacol. 525-31 (1972).
  • the amount of the compound isolated from the urine is multiplied by two to calculate the total amount reaching systemic circulation after administration because the compound is known to be excreted unmetabolized in equal parts in the urine and feces, i.e., approximately 50% of the amount of cromolyn sodium that reaches systemic circulation is excreted in the urine and approximately 50% of the amount of cromolyn sodium that reaches systemic circulation is excreted in the feces.
  • Enhanced lung deposition refers to an increase in drug deposition (deposited lung dose) arising out of, for example, improved efficiency of drug delivery.
  • “Deposited dose” or “deposited lung dose” is the amount of cromolyn or a pharmaceutically-acceptable salt thereof deposited in the lung.
  • the deposited dose or deposited lung dose may be expressed in absolute terms, for example in mg or ⁇ g of API deposited in the lungs.
  • the deposited lung dose may also be expressed in relative terms, for example calculating the amount of API deposited as a percentage of the nominal dose.
  • C max refers to the maximum plasma concentration for an active pharmaceutical ingredient (API).
  • C maxHEN refers to the maximum blood plasma concentration for a nominal dose of the active pharmaceutical ingredient (API) administered with a nebulizer.
  • C maxCONV refers to the maximum blood plasma concentration for a nominal dose of the active pharmaceutical ingredient (API) administered with a conventional inhalation device.
  • the C max of an API can be determined by methods known to those of skill in the art.
  • the C max of an API can be determined by collecting blood samples from a subject at various time points after administration of an API to the subject, separating plasma from the blood samples, extracting the API from the separated plasma samples, e.g., by solid-phase extraction, quantifying the amount of the API extracted from each sample of separated plasma, e.g., by LC-MS/MS, plotting the concentration of API in each sample versus the time of collection after administration, and identifying the peak concentration of the API on the curve.
  • “Enhanced pharmacokinetic profile” means an improvement in some pharmacokinetic parameter.
  • Pharmacokinetic parameters that may be improved include AUC (0-4 or 0-6 or 0-8 h), AUC last , AUC (0- ⁇ ) , T max , T 1/2 , and C max .
  • the enhanced pharmacokinetic profile may be measured quantitatively by comparing a pharmacokinetic parameter obtained for a nominal dose of an active pharmaceutical ingredient (API) administered by one route of administration, such as an inhalation device (e.g., a nebulizer) with the same pharmacokinetic parameter obtained with the same nominal dose of active pharmaceutical ingredient (API) administered by a different route of administration, such as a different type of inhalation device or an oral formulation (e.g., oral tablet, oral capsule, or oral solution).
  • an inhalation device e.g., a nebulizer
  • an oral formulation e.g., oral tablet, oral capsule, or oral solution
  • Blood plasma concentration refers to the concentration of an active pharmaceutical ingredient (API) in the plasma component of blood of a subject or subject population.
  • Subject refers to the animal (especially mammal) or human being treated.
  • a “subject group” or “subject group” has a sufficient number of subjects or subjects to provide a statistically significant average measurement of the relevant pharmacokinetic parameter. All members of the “subject group” or “subject group” have pharmacokinetic parameters for the cromolyn or a pharmaceutically-acceptable salts thereof that fall within statistically normal ranges (i.e., there are no outliers), and no member is included on the basis of non-standard or unusual measurements.
  • Nebulizer refers to a device that turns medications, compositions, formulations, suspensions, and mixtures, etc. into a fine aerosol mist for delivery to the lungs.
  • “Drug absorption” or simply “absorption” typically refers to the process of movement of drug from site of delivery of a drug across a barrier into a blood vessel or the site of action, e.g., a drug being absorbed via the pulmonary capillary beds of the alveoli into the systemic circulation.
  • T max refers to the amount of time necessary for an active pharmaceutical ingredient (API) to attain maximum blood plasma concentration.
  • T maxHEN refers to the amount of time necessary for a nominal dose of an active pharmaceutical ingredient (API) to attain maximum blood plasma concentration after administration with a nebulizer.
  • T maxCONV refers to the amount of time necessary for a nominal dose of an active pharmaceutical ingredient (API) to attain maximum blood plasma concentration after administration with a conventional inhalation device.
  • treat and its grammatical variants (e.g., “to treat,” “treating,” and “treatment”) refer to administration of an active pharmaceutical ingredient to a subject with the purpose of ameliorating or reducing the incidence of one or more symptoms of a condition or disease state in the subject. Such symptoms may be chronic or acute; and such amelioration may be partial or complete.
  • treatment entails administering cromolyn or a pharmaceutically-acceptable salt thereof to a subject via any route of administration disclosed herein.
  • high concentration refers to a concentration greater than 1% by weight.
  • a “high concentration” formulation of cromolyn sodium comprises cromolyn sodium at a concentration of greater than 1% by weight.
  • hypotonic refers to a formulation that has a tonicity less than 295 mOsm/kg.
  • prophylaxis refers to administration of an active pharmaceutical ingredient to a subject with the purpose of reducing the occurrence or recurrence of one or more acute symptoms associated with a disease state or a condition in the subject.
  • prophylaxis entails administering cromolyn or a pharmaceutically-acceptable salt thereof to a subject via any route of administration disclosed herein.
  • prophylaxis includes reduction in the occurrence or recurrence rate of chronic cough due to IPF.
  • prophylaxis is not intended to include complete prevention of onset of a disease state or a condition in a subject who has not previously been identified as suffering from chronic cough due to IPF.
  • a “systemically effective amount” is an amount of cromolyn or a pharmaceutically-acceptable salt thereof in the body of a subject as a whole that is effective for the treatment or prophylaxis of chronic cough due to IPF.
  • a “systemically effective amount” may be expressed, for example, as the mass of cromolyn or a pharmaceutically-acceptable salt thereof, or concentration of cromolyn or a pharmaceutically-acceptable salt thereof, in a subject's plasma.
  • a “systemically effective amount” may differ depending on the formulation of cromolyn or a pharmaceutically-acceptable salt thereof.
  • a “locally effective amount” is an amount of cromolyn or a pharmaceutically-acceptable salt thereof in a particular region of the body of a subject that is effective for the treatment or prophylaxis of chronic cough due to IPF.
  • a “locally effective amount” may be expressed, for example, as the mass of cromolyn or a pharmaceutically-acceptable salt thereof, or concentration of cromolyn or a pharmaceutically-acceptable salt thereof, in a subject's tissue.
  • a “locally effective amount” may differ depending on the formulation of cromolyn or a pharmaceutically-acceptable salt thereof.
  • a difference is “significant” if a person skilled in the art would recognize that the difference is probably real.
  • significance may be determined statistically, in which case two measured parameters may be referred to as statistically significant.
  • statistical significance may be quantified in terms of a stated confidence interval (CI), e.g., greater than 90%, greater than 95%, greater than 98%, etc.
  • CI stated confidence interval
  • statistical significance may be quantified in terms of a p value, e.g., less than 0.5, less than 0.1, less than 0.05, etc. The person skilled in the art will recognize these expressions of significance and will know how to apply them appropriately to the specific parameters that are being compared.
  • PA101 contains 4% (by weight) cromolyn as the active substance, 0.2% sodium chloride as an osmotic agent, 0.02% EDTA as a chelating agent, 1.25% mannitol as a non-ionic osmotic agent, and purified water q.s.
  • PA101 has an osmolality of 200 mOsm/kg.
  • Placebo A contained 0.4% sodium chloride as an osmotic agent, 0.02% EDTA as a chelating agent, 1.25% mannitol as a non-ionic osmotic agent, and purified water q.s., but no cromolyn sodium.
  • Placebo A The osmolality of Placebo A was adjusted to about 200 mOsm/kg.
  • Placebo B contained 0.6% sodium chloride as an osmotic agent, 0.02% EDTA as a chelating agent, and purified water q.s., but no cromolyn sodium or mannitol.
  • the osmolality of Placebo B was adjusted to about 200 mOsm/kg.
  • a primary objective of the study was to assess the safety and tolerability of inhaled PA101 (including the excipient mannitol in the formulation) in IPF subjects with refractory chronic cough.
  • a secondary objective of the study was to assess the efficacy potential of inhaled PA101 after 3 days dosing.
  • the study design was as follows: Phase 1b, randomized, double-blind, single-center, 3-period crossover study in 6 IPF subjects (40-79 years of age) with refractory chronic cough. Each study treatment administered three times daily (TID) for 3 days and one dose the next day (total of 10 doses). 72-hours continuous monitoring for cough count.
  • Table 2 provides a summary of adverse events, divided by severity, type, and treatment.
  • FIG. 1 provides a summary of the average number of coughs at three daytime time points for each subject.
  • FIG. 2 provides a summary of the total number of coughs at three daytime time points for each subject.
  • the number of coughs provided in FIGS. 1 and 2 are based upon subjective subject reports, the following cough counts are based upon an objective measure.
  • the study used the Leicester Cough Monitor (LCM), a validated 24-h automated cough frequency monitor.
  • the LCM requires the subject to wear a microphone adhered to the subject's chest and attached to a monitor (carried with shoulder strap) that is present on the subject 24 hours each day to record all coughs.
  • the study includes two additional subjective measures: Cough Severity and Urge-to-Cough, both provided quantitatively as a measure on a visual analogue scale (VAS).
  • VAS visual analogue scale
  • the subject When using the visual analogue scale (VAS), for example, to measure cough severity, the subject is asked to mark on a 100 mm scale between ‘no cough’ and ‘the worst cough severity’.
  • VAS visual analogue scale
  • urge-to-cough the subject is asked to mark on a 100 mm scale between ‘no urge’ and ‘the worst urge-to-cough’.
  • Table 4 provides the mean, standard deviation (SD) and median scores on the VAS for each parameter by treatment at either day 1 or day 4 of the study.
  • FVC forced vital capacity
  • the primary objective of the study is to determine the systemic availability and pharmacokinetic (PK) profile of single doses of a representative inhaled cromolyn sodium formulation (PA-101) delivered via a nebulizer (eFlow®, PARI) using two different aerosol membranes (30 L and 40 L) in comparison with marketed formulations of cromolyn sodium (oral solution and an inhalation aerosol) in healthy subjects.
  • PK pharmacokinetic
  • the secondary objective of the study is to assess the safety and tolerability of PA-101 in comparison with marketed formulations of cromolyn sodium (oral solution and an inhalation aerosol).
  • the main delivery device for administering PA-101 was the open system eFlow nebulizer using the 30 L aerosol head, which generates aerosol particles with a median size of about 3.0 ⁇ m.
  • the duration of the study was one day.
  • Urine DSCG levels were measured for total DSCG excretion in the urine, and the bioavailability of the DSCG was calculated from the measured levels.
  • Adverse events including gastrointestinal disturbance (e.g., abdominal pain, nausea, vomiting), changes in vital signs, 12-lead ECG and clinical laboratory tests (hematology, chemistry and urinalysis).
  • Pharmacokinetic parameters and plasma concentrations are listed and summarized. The summary statistics are presented as the geometric mean, arithmetic mean, arithmetic standard deviation (SD), min, median, max and n. The geometric statistics are not presented for Tmax. Analysis of variance (ANOVA) including terms for subject and treatment are used to calculate point estimates, and confidence intervals (CI) for treatment differences with respect to PK parameters (90% CI) are calculated.
  • ANOVA Analysis of variance
  • Cromolyn sodium deposited in the lung during inhalation will appear in the plasma, and the AUC would therefore be a surrogate for cromolyn sodium deposited in the lung. Any cromolyn sodium swallowed during inhalation will contribute negligibly to the AUC since the oral bioavailability of cromolyn is only about 1% (Richards et al, J Pharmacol Exp Ther, Vol. 241, No. 3: 1028-1032 (1987)).
  • the AUC data therefore indicate that at the same dose (40 mg), the lung deposition with the 30 L device was surprisingly higher than that with the 40 L device.
  • Table 7 provides a summary of adverse events observed following treatment with PA101 formulations versus placebo or other available cromolyn formulations.
  • PA101 contains 4% (by weight) cromolyn as the active substance, 0.2% Sodium Chloride as an osmotic agent, 0.02% EDTA as a chelating agent, 1.25% mannitol as a non-ionic osmotic agent, and purified water q.s.
  • PA101 has an osmolality of 200 mOsm/kg.
  • PA101-B contains 4% or 6% (by weight) cromolyn as the active substance, 0.2% sodium chloride as an osmotic agent, 0.02% EDTA as a chelating agent, and purified water q.s.
  • PA101-B (40 mg) has an osmolality of 125 mOsm/kg.
  • PA101-B 60 mg) has an osmolality of 135 mOsm/kg.
  • a primary objective of the study was to evaluate the pharmacokinetics, relative bioavailability, and tolerability three different PA101 formulations in healthy subjects.
  • the study was designed as a randomized, double-blind, 4 period cross-over study using 12 healthy volunteers, between 18 and 45 years old.
  • the treatments given were one of the following: 1) 40 mg PA101 (with mannitol), 2) 40 mg PA101B (no mannitol), 3) 60 mg PA101B (no mannitol), and 4) Placebo TID (no mannitol). All treatments administered three times per day (TID) as a single day treatment. Each study treatment separated by a washout period of minimum 24 hrs. All formulations were administered with a Pan eFlow 30 L device. The placebo contained 0.2% sodium chloride as an osmotic agent, 0.02% EDTA as a chelating agent, and purified water q.s. The osmolality of the placebo was about 65 mOsm/kg.
  • Study demographics 13 total subjects, 5 male and 8 female, having a mean age of 28 years old (total range of 21-40 years old).
  • Disposition 13 subjects were randomized. 12 subjects completed the study whereas one subject discontinued during the treatment period 1 (subject was receiving placebo) due to an adverse event (a cough that started 1 minute post-dosing and lasted three minutes).
  • Table 8 provides a summary of the adverse events observed during this study.
  • Tables 9a and 9b provide an accounting of all adverse events observed during this study.
  • PA101 PA101-B 40
  • PA101-B 60
  • N 12
  • N 12
  • N 13
  • System Organ Class Preferred term n (%) n (%) n (%) n (%) n (%) Number of subject with at least one TEAE 5 (41.7) 7 (58.3) 5 (41.7) 7 (53.8)
  • PA101 PA101-B 40
  • PA101-B 60
  • N 12
  • N 12
  • N 12
  • N 13
  • DIZZINESS 1 8.3) 3 (25.0) 2 (16.7) 1 (7.7) HEADACHE 1 (8.3) 2 (16.7) 2 (16.7) 0 (0.0) RESPIRATORY, THORACIC AND 0 (0.0) 3 (25.0) 3 (25.0) 4 (30.8)
  • MEDIASTINAL DISORDERS COUGH 0 (0.0) 0 (0.0) 2 (16.7) 4 (30.8) THROAT IRRITATION 0 (0.0) 1 (8.3) 1 (8.3) 2 (15.4)
  • NASAL CONGESTION 0 (0.0) 1 8.3) 0 (0.0) 0 (0.0) OROPHARYNGEAL PAIN
  • Table 10 provides a summary of adverse events observed during this study related to administration of PA101 or PA101-B.
  • PA101 PA101-B 40
  • PA101-B 60
  • N 12
  • N 12
  • N 13
  • System Organ Class Preferred term n (%) n (%) n (%) n (%) Number of subject with at least one TEAE 0 (0.0) 2 (16.7) 2 (16.7) 4 (30.8) RESPIRATORY, THORACIC AND 0 (0.0) 1 (8.3) 2 (16.7) 4 (30.8) MEDIASTINAL DISORDERS COUGH 0 (0.0) 0 (0.0) 1 (8.3) 4 (30.8) THROAT IRRITATION 0 (0.0) 1 (8.3) 1 (8.3) 2 (15.4) NERVOUS SYSTEM DISORDERS 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) DIZZINESS 0 (0.0) 0 (0.0) 1 (8.3) 0 (0.0) GASTROINTESTINAL DISORDERS 0 (0.0) 1 (8.3) 0 (0.0) 1 (7
  • Table 11 provides a summary of moderate adverse events observed during this study.
  • Table 12 provides the mean and standard deviation (SD) for each pharmacokinetic parameter measured for each PA101 formulation studied.
  • SD standard deviation
  • K e1 is the elimination rate constant that describes the rate at which the cromolyn of PA101 or PA101-B formulations is removed from the subject's system. This measure is equivalent to the fraction of cromolyn that is removed per unit of time (T ⁇ ′, or in this case 1/hours (h)).
  • the pharmacokinetic parameters of the PA101 treatments of the Phase I study (described in Example 2—PK-01) and the Phase II study (described in this Example—PK-02) are compared in Table 13 below.
  • subjects in one of the PK-01, 40 mg group was administered the formulation comprising cromolyn sodium using a Pari eFlow 40 L device, while the formulations were administered to all other subjects in the study using a Pari eFlow 30 L device.
  • the PK-01 study there were three subjects whose plasma values were very high compared to the average, and these outlier values skewed the Cmax and AUC results in the PK-01 study. If the data are analyzed by excluding these outliers, the Cmax and AUC results of the PK-01 and PK-02 studies are comparable. This was supported by the finding that the urine cromolyn levels were similar in the two studies.
  • PA101 formulations from the Phase I and Phase II studies are safe and well-tolerated.
  • the most common adverse events, reported in at least 2 subjects, include cough, throat irritation, dizziness, headache and catheter-site reaction.
  • Treatment-related adverse events include cough, throat irritation, dizziness, dry mouth and nausea.
  • Both the frequency and severity of adverse events are comparable between active and placebo treatments, which was unexpected given that the PA101-B formulations (without mannitol) exhibited osmolalities that were significantly different than formulations comprising mannitol. Accordingly, the majority of adverse events have a mild intensity and transient duration.
  • the PA101-B formulations (at both 40 mg and 60 mg dosages) are well-tolerated with an adverse event (AE) profile similar to PA101.
  • AE adverse event
  • PA101-B formulations (at both 40 mg and 60 mg dosages) have a comparable pharmacokinetic profile to PA101.
  • Example 4 Phase II Safety and Efficacy Study of Cromolyn Formulations in Subjects with Chronic Cough Due to Idiopathic Pulmonary Fibrosis (IPF)
  • the study consists of two treatment periods of 14 days each separated by a Washout Period of 14 days ( ⁇ 2 days) between Period 1 and Period 2.
  • a Screening Visit will be conducted within 14 days before the Baseline Visit of Period 1.
  • the two periods are identical except that in Period 2, subjects are crossed over to the alternate treatment from that received in Period 1, according to a 1:1 randomization scheme.
  • subjects with a daytime cough severity score >40 mm using a linear 100 mm visual analogue scale are placed on 24-hour objective cough count monitoring using the LCM cough monitor.
  • Subjects with an average daytime cough count of at least 15 coughs per hour using LCM at the Screening Visit are eligible for randomization.
  • subjects self-administer study drug (i.e., 40 mg PA101 or Placebo PA101 via eFlow) three times daily (i.e., 8:00 am ⁇ 1 hour, 2:00 ⁇ m ⁇ 1 hour, and 8:00 ⁇ m ⁇ 1 hour) for 14 consecutive days of each period (e.g., Days 1-14).
  • Subjects attend a Pre-study Visit (Visit 1, Day ⁇ 1) at the clinic in the morning prior to the Baseline/Treatment Visit (Visit 2, Day 1) and a cough count device (LCM) is dispensed for measurement of baseline 24-hour cough count.
  • Subjects return to the clinic next day in the morning (Visit 2, Day 1) to return the devices, assessment of quality of life measures, and to receive the first dose of the study treatment. Additional treatment visits during the Treatment Period occur on Day 7 ⁇ 1 day (Visit 3) and Day 15 ⁇ 1 day (Visit 5). Subjects visit the clinic on Day 7 ⁇ 1 day (Visit 3) and Day 14 ⁇ 1 day (Visit 4) in the morning and the LCM device is dispensed for measurement of 24-hour cough count.
  • Study assessments include assessment of quality of life (LCQ and K-BILD), cough severity (VAS), pulmonary function tests (forced expiratory volume in one second [FEV1], forced vital capacity [FVC], and FEV1/FVC ratio), fraction of exhaled nitric oxide (FeNO), and safety assessments (AEs, vital signs, and ECG) on Days 1, 7 and 15 of each treatment period.
  • a safety follow-up call is placed within 7 ⁇ 2 days following the last study treatment.
  • Clinical safety laboratory samples are collected at the start and end of the treatment of each treatment period (Screening Visit and Visit 5 during the Treatment Period 1, and at Visit 2 and Visit 5 during the Treatment Period 2). All post-dose study procedures are conducted from time 0.
  • Time 0 is defined as the start of the first study drug administration (i.e., when the nebulizer has been turned on) of each period.
  • subjects are allowed to use antifibrotic therapy i.e., pirfenidone, nintedanib, and N-acetylcysteine) during the course of the study provided that the dose is stabilized at least 3 months prior to the Screening visit and throughout the study period.
  • Subjects are not allowed to use the following drugs (i.e., prednisone, narcotic antitussives, baclofen, gabapentin, inhaled corticosteroids, benzonatate, dextromethorphan, carbetapentane, and H1 antihistamines, leukotriene modifiers, and cromolyn sodium) for at least 2 weeks prior to the Screening Visit and throughout the study.
  • Drugs containing bronchodilators including beta-2 agonists and anticholinergics are not allowed for at least 1 week prior to the Baseline Visit and during the study.
  • PA101 contains 4% (by weight) cromolyn as the active substance, 0.2% Sodium Chloride as an osmotic agent, 0.02% EDTA as a chelating agent, 1.25% mannitol as a non-ionic osmotic agent, and purified water q.s.
  • PA101 has an osmolality of 200 mOsm/kg.
  • a primary objective of the study was to assess the effectiveness of inhaled PA101 delivered via a Pan eFlow 30 L nebulizer for treating chronic cough due to IPF.
  • the study design is provided graphically in FIG. 4 .
  • Inclusion Criteria 1) male or female subjects age 40 through 79 years, inclusive of the endpoints, 2) diagnosis of Idiopathic Pulmonary Fibrosis (IPF) with the consensus of the multidisciplinary team based on the presence of definitive or possible usual interstitial pneumonia (UIP) pattern on high-resolution computed tomography (HRCT) and after excluding alternative diagnoses, including lung diseases associated with environmental and occupational exposure, with connective tissue diseases and with drugs, 3) chronic cough present for at least 8 weeks and not responsive to current therapies, 4) daytime cough severity score on visual analogue scale >40 mm at the Screening Visit, 5) daytime average cough count of at least 15 coughs per hour using objective cough count monitor at the Screening Visit, 6) transfer capacity for carbon monoxide corrected for hemoglobin (TLCOc) >25% predicted value within 12 months of the Screening Visit and Forced Vital Capacity (FVC) >50% predicted value within 1 month of the Screening Visit, and 7) willingness and ability to provide written informed consent.
  • IPF Idiopathic Pulmon
  • Exclusion Criteria 1) current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the subject at risk or compromise the quality of the study data as determined by the investigator, 2) significant coronary artery disease (i.e., myocardial infarction within 6 months or unstable angina within 1 month of the Screening Visit), 3) an upper or lower respiratory tract infection within 4 weeks of the Screening Visit, 4) acute exacerbation of IPF within 3 months of the Screening Visit, 5) long-term daily oxygen therapy (>10 hours/day), 6) presence of pulmonary arterial hypertension with limitation of activity, 7) history of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma or cervix carcinoma in situ, 8) current or recent history (previous 12 months) of excessive use or abuse of alcohol, 9) current or recent history (previous 12 months) of abusing legal drugs or use of illegal drugs or substances, 10) participation in any other investigational drug study within 4 weeks prior to the Screening Visit, 11)
  • Table 14 provides the demographics of the study participants.
  • Table 15 summarizes the treatment emergent adverse events (AEs) reported for at least two subjects having chronic cough due to IPF.
  • FIG. 5 provides a summary of the daytime average cough/hour in subjects with chronic cough due to IPF receiving either PA101 or a placebo at baseline, Day 7, and Day 14 of the study.
  • a statistically significant difference emerges at Days 7 and 14 for the PA101-treated subjects.
  • this statistically significant difference can be expressed as both a placebo-adjusted (PBO-adjusted) reduction in cough frequency (see FIG. 7 ) and a least squares (LS) means ratio with a 95% confidence interval (CI) (see FIGS. 7 and 8 ).
  • PBO-adjusted placebo-adjusted
  • LS least squares
  • CI 95% confidence interval
  • Table 16 summarizes the data shown graphically in FIGS. 7 and 8 .
  • Table 17 summarizes the data shown graphically in FIGS. 7 and 8 .
  • FIG. 12 provides a summary of the nighttime average cough/hour in subjects with chronic cough due to IPF receiving either PA101 or a placebo at baseline, Day 7, and Day 14 of the study. Similar to the analysis performed for daytime cough, FIG. 13 provides the change from baseline for nighttime cough at Days 7 and 14 for the PA101-treated subjects.
  • Table 18 summarizes the data shown graphically in FIGS. 12 and 13 .
  • Table 19 summarizes the data shown graphically in FIGS. 15-17 .
  • FIG. 18 synthesizes the data from daytime, nighttime and 24-hour cough/hour analyses to generate a 24-hour cough profile for subjects in this study with chronic cough due to IPF who receive either placebo or PA101.
  • the average cough/hour rates over a 24-hour window are drawn contrasting baseline rates to those rates demonstrated following 14 days of administration of either the placebo or PA101.
  • the PA101-treated group shows a statistically-significant and clinically relevant reduction in cough/hour rates by Day 14, particularly from the hours of 8 am to 11 pm.
  • Table 21 summarizes the change from baseline in the Leicester Cough Questionnaire measuring Quality of Life.
  • Table 22 summarizes the cough specific Quality of Life in Responders. Responders are defined herein as those subjects with chronic cough due to IPF who experience a greater than 30% reduction in the average daytime cough following treatment with a composition of the disclosure, or in this study, PA101.
  • Table 24 summarizes the change from baseline in K-BILD psychological domain measuring Quality of Life using a mixed score model in subjects with chronic cough due to IPF treated with either placebo or PA101.
  • Table 25 summarizes the change from baseline in K-BILD breathlessness and activities domain measuring Quality of Life using a mixed score model in subjects with chronic cough due to IPF treated with either placebo or PA101.
  • Table 26 summarizes the change from baseline in K-BILD chest symptoms domain measuring Quality of Life using a mixed score model in subjects with chronic cough due to IPF treated with either placebo or PA101.
  • Table 27 summarizes the change from baseline in K-BILD total score measuring Quality of Life using a mixed score model in subjects with chronic cough due to IPF treated with either placebo or PA101.
  • Table 28 summarizes the data from measuring cough severity by VAS in subjects with chronic cough due to IPF treated with either placebo or PA101. Cough severity was measured by Visual Analog Scale (VAS).
  • VAS Visual Analog Scale
  • VAS visual analogue scale
  • Table 29 summarizes the change from baseline in cough severity by VAS in subjects with chronic cough due to IPF treated with either placebo or PA101.
  • Table 30 summarizes the data from measuring cough severity by VAS in Responders.
  • the LCQ and VAS scores in Responders were compared (see FIG. 19 ).
  • the data indicate a significant difference in VAS scores in Responders treated with PA101 between baseline and day 14.
  • This subjective measure of cough severity corroborates the objective measure of cough frequency measured by using a cough monitor. Both methods demonstrate a clinically relevant reduction in symptoms of chronic cough due to IPF following 14 days of treatment with PA101.
  • the study consists of two treatment periods of 14 days each separated by a Washout Period of 14 days ( ⁇ 2 days) between Period 1 and Period 2.
  • a Screening Visit will be conducted within 14 days before the Baseline Visit of Period 1.
  • the two periods are identical except that in Period 2, subjects were crossed over to the alternate treatment from that received in Period 1, according to a 1:1 randomization scheme.
  • subjects with a daytime cough severity score >40 mm using a linear 100 mm visual analogue scale are placed on 24-hour objective cough count monitoring using the LCM cough monitor.
  • Subjects with an average daytime cough count of at least 15 coughs per hour using LCM at the Screening Visit are eligible for randomization.
  • subjects self-administer study drug (i.e., 40 mg PA101 or Placebo PA101 via a Pari eFlow 30 L device) three times daily (i.e., 8:00 am ⁇ 1 hour, 2:00 ⁇ m ⁇ 1 hour, and 8:00 ⁇ m ⁇ 1 hour) for 14 consecutive days of each period (e.g., Days 1-14).
  • Subjects attend a Pre-study Visit (Visit 1, Day ⁇ 1) at the clinic in the morning prior to the Baseline/Treatment Visit (Visit 2, Day 1) and a cough count device (LCM) is dispensed for measurement of baseline 24-hour cough count.
  • a Pre-study Visit Visit 1, Day ⁇ 1
  • Baseline/Treatment Visit Visit 2, Day 1
  • a cough count device is dispensed for measurement of baseline 24-hour cough count.
  • Subjects return to the clinic next day in the morning (Visit 2, Day 1) to return the devices, assessment of quality of life measures, and to receive the first dose of the study treatment. Additional treatment visits during the Treatment Period occur on Day 7 ⁇ 1 day (Visit 3) and Day 15 ⁇ 1 day (Visit 5). Subjects visit the clinic on Day 7 ⁇ 1 day (Visit 3) and Day 14 ⁇ 1 day (Visit 4) in the morning and the LCM device is dispensed for measurement of 24-hour cough count.
  • Study assessments include assessment of quality of life (LCQ and K-BILD), cough severity (VAS), pulmonary function tests (forced expiratory volume in one second [FEV1], forced vital capacity [FVC], and FEV1/FVC ratio), fraction of exhaled nitric oxide (FeNO), and safety assessments (AEs, vital signs, and ECG) on Days 1, 7 and 15 of each treatment period.
  • a safety follow-up call is placed within 7 ⁇ 2 days following the last study treatment.
  • Clinical safety laboratory samples are collected at the start and end of the treatment of each treatment period (Screening Visit and Visit 5 during the Treatment Period 1, and at Visit 2 and Visit 5 during the Treatment Period 2). All post-dose study procedures are conducted from time 0.
  • Time 0 is defined as the start of the first study drug administration (i.e., when the nebulizer has been turned on) of each period.
  • Subjects are not allowed to use the following drugs (i.e., prednisone, narcotic antitussives, baclofen, gabapentin, inhaled corticosteroids, benzonatate, dextromethorphan, carbetapentane, and H1 antihistamines, leukotriene modifiers, and cromolyn sodium) for at least 2 weeks prior to the Screening Visit and throughout the study.
  • Drugs containing bronchodilators including beta-2 agonists and anticholinergics are not allowed for at least 1 week prior to the Baseline Visit and during the study.
  • PA101 contains 4% (by weight) cromolyn as the active substance, 0.2% Sodium Chloride as an osmotic agent, 0.02% EDTA as a chelating agent, 1.25% mannitol as a non-ionic osmotic agent, and purified water q.s.
  • PA101 has an osmolality of 200 mOsm/kg.
  • a primary objective of the study was to assess the effectiveness of inhaled PA101 delivered via an eFlow nebulizer for treating chronic idiopathic cough.
  • the study design is provided graphically in FIG. 20 .
  • the inclusion criteria of the chronic idiopathic cough (CIC) cohort are: 1) male or female subjects age 18 through 75 years, inclusive of the endpoints, 2) chronic cough that has been present for at least 8 weeks, 3) diagnosis of chronic idiopathic cough (CIC) that is unresponsive to targeted treatment for identified underlying triggers (i.e., post-nasal drip, asthmatic/non-asthmatic eosinophilic bronchitis, and gastro-esophageal reflux disease), 4) cough score on visual analogue scale of ⁇ 40 mm at the Screening Visit, 5) daytime average cough count of at least 15 coughs per hour using objective cough count monitor at the Screening Visit, and 6) willingness and ability to provide written informed consent.
  • triggers i.e., post-nasal drip, asthmatic/non-asthmatic eosinophilic bronchitis, and gastro-esophageal reflux disease
  • the exclusion criteria of the chronic idiopathic cough (CIC) cohort are: 1) current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the subject at risk or compromise the quality of the study data as determined by the investigator, 2) an upper or lower respiratory tract infection within 4 weeks of the Screening Visit, 3) history of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma or cervix carcinoma in situ, 4) current or recent history (previous 12 months) of excessive use or abuse of alcohol, 5) current or recent history (previous 12 months) of abusing legal drugs or use of illegal drugs or substances, 5) participation in any other investigational drug study within 4 weeks prior to the Screening Visit, 6) use of the following drugs within 2 weeks of the Screening Visit: Prednisone, narcotic antitussives, baclofen, gabapentin, inhaled corticosteroids, benzonatate, dextromethorphan, carbetapentane
  • Table 31 summarizes the CIC cohort demographics.
  • Example 4 this study demonstrates that the use of PA101 is safe as the number of adverse events observed in subjects receiving PA101 and subjects receiving the placebo is not statistically significantly different.
  • Table 32 summarizes the Treatment Emergent Adverse Events (AEs) observed in at least two subjects of the CIC cohort.
  • Cough count was measured by Leicester Cough Monitor (LCM). Table 33 provides a summary of the daytime average cough/hour in subjects with CIC.
  • Table 34 provides a summary of the change from baseline in log transformed daytime average cough/hour in subjects with CIC. This data is provided graphically in FIG. 23 .
  • FIG. 21 The individual average daytime cough/hour rates for the CIC cohort are provided in FIG. 21 at baseline and Day 14.
  • FIG. 22 depicts the change from baseline log transformed daytime average cough/hour for the CIC cohort.
  • the number of subjects responsive to treatment with PA101 versus placebo for CIC is shown in FIG. 24 .
  • FIG. 22 The 24-hour average cough/hour rates for the CIC cohort are provided in FIG. 22 at baseline, Day 7 and Day 14.
  • FIG. 25 depicts the change from baseline log transformed daytime average cough/hour for the CIC cohort.
  • Table 35 provides a summary of the change from baseline in log transformed 24-hour average cough/hour in subjects with CIC.
  • Table 37 summarizes the changes from baseline from the Leicester Cough Questionnaire for the CIC cohort.
  • the study includes an additional subjective measure: Cough Severity, provided quantitatively as a measure on a visual analogue scale (VAS).
  • VAS visual analogue scale
  • Table 38 provides the mean, standard deviation (SD) and median scores on the VAS for each parameter by treatment at either day 7 or day 14 of the study for the CIC cohort.
  • Table 39 summarizes the changes from baseline for Cough Severity as measured by the VAS score for the CIC cohort.
  • Tables 40a and 40b summarize the treatment period effect using daytime average count for the CIC cohort.
  • PA101 has a very good safety profile for the treatment of CIC.
  • Example 6 Cromolyn Sodium Formulations for Treatment of Chronic Cough Due to IPF Versus Chronic Idiopathic Cough (CIC)
  • Example 4 demonstrate that the compositions of the disclosure, of which PA101 is an exemplary formulation, are safe and efficacious for the treatment of chronic cough due to IPF.
  • the data from Example 5 demonstrate that the compositions of the disclosure, of which PA101 is an exemplary formulation, are safe but are not efficacious for the treatment of chronic idiopathic cough (CIC).
  • FIGS. 26-29 compare the results of the daytime and 24-hour average cough/hour data between subjects with chronic cough due to IPF (Example 4) versus subjects with chronic idiopathic cough (CIC) (Example 5).
  • the pharmacokinetic parameters in subjects administered PA101 (with mannitol) and PA101-B (without mannitol) are expected to be similar in subjects with chronic cough associated with IPF.
  • compositions and formulations of the disclosure are both physically and chemically stable.
  • Table 41 demonstrates that each formulation remains clear, and, therefore, free of any precipitate, from manufacture through the 24 month time point (i.e. for at least 24 months) when the formulations are stored at 25° C.
  • Table 42 demonstrates that each formulation remains clear, and, therefore, free of any precipitate, from manufacture through the 24 month time point (i.e. for at least 24 months) when the formulations are stored at 40° C.
  • Table 41 demonstrates that each formulation maintains consistent appearance, pH, osmolality assay and related substances from manufacture through the 24 month time point (i.e. for at least 24 months) when the formulations are stored at 25° C.
  • Table 42 demonstrates that each formulation maintains consistent appearance, pH, osmolality, assay and related substances from manufacture through the 6 month time point (i.e. for at least 6 months) when the formulations are stored at 40° C.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US15/887,825 2016-08-31 2018-02-02 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis Abandoned US20180193305A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/887,825 US20180193305A1 (en) 2016-08-31 2018-02-02 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662381914P 2016-08-31 2016-08-31
US201662417898P 2016-11-04 2016-11-04
PCT/US2017/049205 WO2018044942A1 (en) 2016-08-31 2017-08-29 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US15/887,825 US20180193305A1 (en) 2016-08-31 2018-02-02 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/049205 Continuation WO2018044942A1 (en) 2016-08-31 2017-08-29 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis

Publications (1)

Publication Number Publication Date
US20180193305A1 true US20180193305A1 (en) 2018-07-12

Family

ID=61301476

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/887,825 Abandoned US20180193305A1 (en) 2016-08-31 2018-02-02 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US15/887,830 Expired - Fee Related US10265267B2 (en) 2016-08-31 2018-02-02 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US16/277,689 Expired - Fee Related US10463613B2 (en) 2016-08-31 2019-02-15 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US16/576,487 Abandoned US20200155452A1 (en) 2016-08-31 2019-09-19 Cromolyn Compositions for Treatment of Chronic Cough Due to Idiopathic Pulmonary Fibrosis

Family Applications After (3)

Application Number Title Priority Date Filing Date
US15/887,830 Expired - Fee Related US10265267B2 (en) 2016-08-31 2018-02-02 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US16/277,689 Expired - Fee Related US10463613B2 (en) 2016-08-31 2019-02-15 Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US16/576,487 Abandoned US20200155452A1 (en) 2016-08-31 2019-09-19 Cromolyn Compositions for Treatment of Chronic Cough Due to Idiopathic Pulmonary Fibrosis

Country Status (7)

Country Link
US (4) US20180193305A1 (enExample)
EP (1) EP3506893A4 (enExample)
JP (1) JP2019528320A (enExample)
CN (1) CN110139646A (enExample)
AU (1) AU2017321495A1 (enExample)
CA (1) CA3035528A1 (enExample)
WO (1) WO2018044942A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255394A4 (en) * 2020-12-07 2024-10-09 MannKind Corporation METHOD AND COMPOSITION FOR THE TREATMENT OF PULMONARY FIBROSIS

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
AU2017339366A1 (en) * 2016-10-07 2019-04-11 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
US11311505B2 (en) * 2017-02-24 2022-04-26 Cellular Sciences, Inc. Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts
EP3687500A1 (en) * 2017-09-29 2020-08-05 Crititech, Inc. Glucocorticoid particles and their use
CN118477079A (zh) * 2018-07-23 2024-08-13 特雷维治疗股份有限公司 慢性咳嗽、呼吸急促和呼吸困难的治疗
CN110833538A (zh) * 2018-08-17 2020-02-25 北京盈科瑞创新药物研究有限公司 一种吸入用色甘酸钠溶液制剂及其制备方法和应用
WO2020097686A1 (en) * 2018-11-14 2020-05-22 Holman Pharmaceuticals Pty Ltd Compositions and uses thereof
CN111388456A (zh) * 2019-01-03 2020-07-10 江苏康缘药业股份有限公司 一种色甘酸钠雾化吸入溶液及其制备方法
US10709414B1 (en) 2019-10-21 2020-07-14 Sonavi Labs, Inc. Predicting a respiratory event based on trend information, and applications thereof
US10709353B1 (en) 2019-10-21 2020-07-14 Sonavi Labs, Inc. Detecting a respiratory abnormality using a convolution, and applications thereof
US10702239B1 (en) 2019-10-21 2020-07-07 Sonavi Labs, Inc. Predicting characteristics of a future respiratory event, and applications thereof
US10750976B1 (en) * 2019-10-21 2020-08-25 Sonavi Labs, Inc. Digital stethoscope for counting coughs, and applications thereof
US10716534B1 (en) 2019-10-21 2020-07-21 Sonavi Labs, Inc. Base station for a digital stethoscope, and applications thereof
US12433506B2 (en) * 2019-10-21 2025-10-07 Sonavi Labs, Inc. Digital stethoscope for counting coughs, and applications thereof
WO2021142288A1 (en) 2020-01-10 2021-07-15 Trevi Therapeutics, Inc. Methods of administering nalbuphine
KR20250068882A (ko) * 2023-11-10 2025-05-19 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 건조 분말 흡입 제형 및 이의 제조방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140024217A1 (en) * 2011-03-29 2014-01-23 Fujifilm Corporation Method for forming resist patterns and method for producing patterend substrates employing the resist patterns
US9962363B2 (en) * 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders

Family Cites Families (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1144905A (en) 1965-03-25 1969-03-12 Fisons Pharmaceuticals Ltd Substituted bis-(2-carboxy-chromonyl-oxy) derivatives and preparation and pharmaceutical compositions thereof
US3777033A (en) 1965-03-25 1973-12-04 Fisons Pharmaceuticals Ltd Bis-chromonyl pharmaceutical composi-tion and methods
US3686320A (en) 1965-03-25 1972-08-22 Fisons Pharmaceuticals Ltd Bis-phenoxy compounds
US3686412A (en) 1965-03-25 1972-08-22 Colin Fitzmaurice Compositions containing bis-chromonyl compounds for inhibiting antigen-antibody reactions
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3993073A (en) 1969-04-01 1976-11-23 Alza Corporation Novel drug delivery device
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3720690A (en) 1970-04-10 1973-03-13 Fisons Pharmaceuticals Ltd Pharmaceutically active bis-carboxychromone compounds
US3683320A (en) 1970-05-08 1972-08-08 Bunker Ramo Coaxial cable connectors
CA958714A (en) 1970-09-03 1974-12-03 Peter B. Johnson Bis-chromone derivatives
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en) 1971-06-04 1973-05-08 Alza Corp Bandage for the controlled metering of topical drugs to the skin
US3996934A (en) 1971-08-09 1976-12-14 Alza Corporation Medical bandage
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
BE795384A (fr) 1972-02-14 1973-08-13 Ici Ltd Pansements
US4152448A (en) 1972-02-15 1979-05-01 Fisons Limited Method and composition for the treatment of a condition of the gastro intestinal tract
US3921636A (en) 1973-01-15 1975-11-25 Alza Corp Novel drug delivery device
HK38179A (en) 1973-12-19 1979-06-22 Fisons Ltd Topical compositions
US3993072A (en) 1974-08-28 1976-11-23 Alza Corporation Microporous drug delivery device
US4151273A (en) 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US3972995A (en) 1975-04-14 1976-08-03 American Home Products Corporation Dosage form
US4067992A (en) 1975-09-10 1978-01-10 Fisons Limited Method of treating a psychiatric condition
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4031894A (en) 1975-12-08 1977-06-28 Alza Corporation Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en) 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4189571A (en) 1978-02-07 1980-02-19 Fisons Limited Esters of cromoglycates
JPS5562012A (en) 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
US4230105A (en) 1978-11-13 1980-10-28 Merck & Co., Inc. Transdermal delivery of drugs
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4268519A (en) 1979-06-05 1981-05-19 Fisons Limited Method of treating otitis media
CA1146866A (en) 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en) 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
FR2505798B1 (fr) 1981-05-14 1986-07-25 Pari Symac Perfectionnement aux dispositifs comportant un ressort helicoidal utilise comme organe de transfert, d'extraction, de dosage ou de melange
DE3365744D1 (en) 1982-01-22 1986-10-09 Fisons Plc Liposome and sodium cromoglycate compositions, and methods for their preparation
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4996296A (en) 1983-07-27 1991-02-26 Yeda Research & Development Co., Ltd. Cromolyn binding protein in highly purifed form, and methods for the isolation thereof
US4683135A (en) 1983-07-27 1987-07-28 Yeda Research And Development Co., Ltd. DSCG binding protein and process for preparing same
GB8322178D0 (en) 1983-08-17 1983-09-21 Sterwin Ag Preparing aerosol compositions
US4634699A (en) 1983-11-30 1987-01-06 Burroughs Wellcome Co. Branched chain phenothiazine
GB8332450D0 (en) 1983-12-06 1984-01-11 Fisons Plc Method of treatment
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
GB2167300B (en) 1984-11-23 1988-11-23 Fisons Plc Formulations
JPH0662601B2 (ja) 1985-08-16 1994-08-17 京都薬品工業株式会社 クロモグリク酸誘導体および抗アレルギ−剤
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5231170A (en) 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
EP0304802B1 (en) 1987-08-25 1993-03-31 Dr. Kübler GmbH Pharmaceutical composition and the use thereof
US4906476A (en) 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
EP0413583A3 (en) 1989-08-18 1991-07-17 Dey Laboratories; Inc. Clear, stable cromolyn formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5280784A (en) 1990-09-19 1994-01-25 Paul Ritzau Pari-Werk Gmbh Device in particular and inhalating device for treating the lung and the respiratory tracts
US5753208A (en) 1990-11-09 1998-05-19 Egis Gyogyszergyar Antiasthmatic aerosol preparation of sodium cromoglycate
US5633009A (en) 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
ES2082732T3 (es) 1990-12-05 1997-12-16 Gen Hospital Corp Tratamiento de la vasoconstriccion pulmonar reversible y de la broncoconstriccion.
EP0504459B1 (de) 1991-03-21 1996-06-05 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
US6123924A (en) 1991-09-25 2000-09-26 Fisons Plc Pressurized aerosol inhalation compositions
ATE121971T1 (de) 1991-11-07 1995-05-15 Ritzau Pari Werk Gmbh Paul Flüssigkeitszerstäubervorrichtung.
EP0540775B1 (de) 1991-11-07 1997-07-23 PAUL RITZAU PARI-WERK GmbH Vernebler insbesondere zur Anwendung in Geräten für die Inhalationstherapie
US5618842A (en) 1991-12-31 1997-04-08 Lifegroup S.P.A. N-acyl derivatives of aminoalcohols with polycarboxylic acids able to modulate mast cells in inflammatory processes having neuroimmunogenic origin
US5340591A (en) 1992-01-24 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5281420A (en) 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
GB9214390D0 (en) 1992-07-07 1992-08-19 Fisons Plc Formulations
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
DE4225928A1 (de) 1992-08-05 1994-02-10 Ritzau Pari Werk Gmbh Paul Zerstäubervorrichtung mit Heizeinrichtung
US5700485A (en) 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
DE4310575C1 (de) 1993-03-31 1994-09-15 Ritzau Pari Werk Gmbh Paul Vorrichtung zum Erzeugen von Aerosolpulsen
GB9317752D0 (en) 1993-08-26 1993-10-13 Fisons Plc New pharmaceutical use
DE59308788D1 (de) 1993-12-17 1998-08-20 Pari Gmbh Zerstäuberdüse
US5508451A (en) 1994-07-07 1996-04-16 Hoechst Celanese Corporation Process for the preparation of dialkali metal cromoglycates
US5665378A (en) 1994-09-30 1997-09-09 Davis; Roosevelt Transdermal therapeutic formulation
US6000394A (en) 1994-10-26 1999-12-14 Paul Rizau Pari-Werk Gmbh Generation of an aerosol of an exact dose
US5552436A (en) 1995-04-03 1996-09-03 Ascent Pharmaceuticals, Inc. Process for treating hemangioma
US5576346A (en) 1995-04-03 1996-11-19 Ascent Pharmaceuticals, Inc. Process for treating uremic pruritus
GB9507768D0 (en) 1995-04-13 1995-05-31 Glaxo Group Ltd Method of apparatus
DE19520622C2 (de) 1995-06-06 2003-05-15 Pari Gmbh Vorrichtung zum Vernebeln von Fluiden
SE9502244D0 (sv) 1995-06-20 1995-06-20 Bioglan Ab A composition and a process for the preparation thereof
GB9513218D0 (en) 1995-06-29 1995-09-06 Fisons Plc Inhalation device and method
US6004949A (en) 1995-12-27 1999-12-21 Showa Yakuhin Kako Co., Ltd. Aqueous composition containing cromoglycic acid
DE19602628C2 (de) 1996-01-25 2000-06-29 Pari Gmbh Vernebler
US6923983B2 (en) 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6929801B2 (en) 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US5824669A (en) 1996-03-22 1998-10-20 Nitromed, Inc. Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
AU2458697A (en) 1996-04-18 1997-11-07 Alcon Laboratories, Inc. Calcium channel blockers as human conjunctival mast cell degranulation inhibitors for treating ocular allergic conditions
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
EP1014979A4 (en) 1997-06-09 2003-08-20 Bridge Pharma Inc CONNECTIONS WITH COMBINED ANTIHISTAMINIC AND FAST-CELL STABILIZING ACTIVITY FOR OPHTHALMOLOGICAL USE
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
DE19734022C2 (de) 1997-08-06 2000-06-21 Pari Gmbh Inhalationstherapiegerät mit einem Ventil zur Begrenzung des Inspirationsflusses
US5952353A (en) 1997-09-19 1999-09-14 Auburn University Treating/preventing heart failure via inhibition of mast cell degranulation
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
NZ503464A (en) 1997-09-29 2002-05-31 Inhale Therapeutic Syst Perforated microparticles containing a bioactive agent for pulmonary delivery
US5869090A (en) 1998-01-20 1999-02-09 Rosenbaum; Jerry Transdermal delivery of dehydroepiandrosterone
US6365180B1 (en) 1998-01-20 2002-04-02 Glenn A. Meyer Oral liquid compositions
US6323219B1 (en) 1998-04-02 2001-11-27 Ortho-Mcneil Pharmaceutical, Inc. Methods for treating immunomediated inflammatory disorders
GB9807232D0 (en) 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
GB9810949D0 (en) 1998-05-22 1998-07-22 Hewlett Healthcare Limited Formulation
DE19827228C2 (de) 1998-06-18 2000-07-13 Pari Gmbh Flüssigkeitszerstäubervorrichtung
US6946144B1 (en) 1998-07-08 2005-09-20 Oryxe Transdermal delivery system
US6585958B1 (en) 1998-07-24 2003-07-01 Jago Research Ag Medicinal aerosol formulations
DK1102579T3 (da) 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
CN1313439C (zh) 1998-08-07 2007-05-02 艾米斯菲尔技术有限公司 用于送递活性剂的化合物和组合物
GB9824604D0 (en) 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
EP2191718A1 (en) 1998-12-22 2010-06-02 The University of North Carolina at Chapel Hill Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs
WO2000040203A2 (en) 1999-01-08 2000-07-13 Emisphere Technologies, Inc. Polymeric delivery agents and delivery agent compounds
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
WO2000066206A2 (en) 1999-05-03 2000-11-09 Battelle Memorial Institute Compositions for aerosolization and inhalation
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6586008B1 (en) 1999-08-25 2003-07-01 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles during spray drying
CA2383491A1 (en) 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Large porous particles by spray-drying
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
DE19962110C2 (de) 1999-12-22 2003-06-12 Pari Gmbh Inhalationsvernebler mit einstückigem Ventilelement
US6596261B1 (en) 2000-01-25 2003-07-22 Aeropharm Technology Incorporated Method of administering a medicinal aerosol formulation
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8257744B2 (en) 2000-07-07 2012-09-04 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
NZ533223A (en) 2001-11-14 2007-04-27 Centocor Inc Anti-il-6 antibodies, compositions, methods and uses
WO2003045331A2 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6596284B1 (en) 2002-04-30 2003-07-22 Thomas E. Fleming Treating eczema with a combination of isotonic saline ocean® and nasal mast cell stabilizers
CA2489280A1 (en) 2002-06-14 2003-12-24 Centocor, Inc. Modified "s" antibodies
AU2003243785A1 (en) 2002-06-27 2004-01-19 Centocor, Inc. Cngh0004 polypeptides, antibodies, compositions, methods and uses
AU2003247641A1 (en) 2002-06-27 2004-01-19 Centocor, Inc. Cngh0005 polypeptides, antibodies, compositions, methods and uses
US20040053902A1 (en) 2002-09-13 2004-03-18 Smith C. Steven Novel composition and method for treatment of upper respiratory conditions
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
SE0203687D0 (sv) 2002-12-13 2002-12-13 Ian Harwigsson Med Adagit Fa Pharmaceutical Porous Particles
CA2520853A1 (en) 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
JP2007526208A (ja) 2003-04-11 2007-09-13 メディミューン，インコーポレーテッド 呼吸器の症状を治療又は予防する方法
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
US20050033029A1 (en) 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
US20050026880A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US20050232923A1 (en) 2003-11-05 2005-10-20 Li Yan Methods and compositions for treating MCP-1 related pathologies
US20060078558A1 (en) 2003-11-12 2006-04-13 Whitsett Jeffrey A Diagnosis, prognosis and treatment of pulmonary diseases
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
US20050191246A1 (en) 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
WO2005063732A1 (en) 2003-12-23 2005-07-14 Microbia, Inc. Compounds and methods for the treatment of asthma
IL160936A0 (en) 2004-02-05 2004-08-31 Scott A Cordray Nasal spray and wash
US20050266005A1 (en) 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
AU2005249410A1 (en) 2004-05-14 2005-12-15 Emisphere Technologies, Inc. Aryl ketone compounds and compositions for delivering active agents
JP4468361B2 (ja) 2004-05-26 2010-05-26 株式会社リバース・プロテオミクス研究所 新規創薬ターゲットならびにこれに作用する医薬
WO2006029182A2 (en) 2004-09-07 2006-03-16 The La Jolla Institute For Molecular Medicine Use of mdl-100,907 for treatment of allergic and eosinophil mediated diseases
EP1799260A4 (en) 2004-09-29 2011-09-28 Centocor Inc ANTI-AMYLOID ANTIBODIES, COMPOSITIONS, TECHNIQUES AND USES
JP2008546634A (ja) 2005-03-16 2008-12-25 ハネウェル・インターナショナル・インコーポレーテッド 医薬送達製剤、デバイス及び方法
WO2006105538A2 (en) 2005-03-31 2006-10-05 Centocor, Inc. Methods and compositions for treating il-21 related pathologies
EP1712220A1 (en) 2005-04-15 2006-10-18 PARI GmbH Spezialisten für effektive Inhalation Pharmaceutical aerosol composition
AU2012238334A1 (en) 2005-06-30 2012-11-01 Abbvie Inc. IL-12/p40 binding proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
GB0520794D0 (en) 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
US7566743B2 (en) 2005-11-18 2009-07-28 Mark Glazman System and method for medical treatment
EP1962869B1 (en) 2005-12-21 2013-03-20 SolAeroMed Inc. Treatment of respiratory diseases
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
DE102006001113B3 (de) 2006-01-09 2007-06-28 Pari GmbH Spezialisten für effektive Inhalation Aerosoltherapievorrichtung
US8263645B2 (en) 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
PL1991201T3 (pl) 2006-02-10 2018-09-28 Pari Pharma Gmbh Nebulizowane antybiotyki do terapii inhalacyjnej
US20070219223A1 (en) 2006-03-07 2007-09-20 Endacea, Inc. Compositions and methods for treating respiratory disorders
US20080035141A1 (en) 2006-06-16 2008-02-14 Warner W R Aerosolized therapy kit
WO2008002893A2 (en) 2006-06-29 2008-01-03 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
US8445437B2 (en) 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
KR101625961B1 (ko) 2006-09-08 2016-05-31 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
US20080078382A1 (en) 2006-09-20 2008-04-03 Lemahieu Edward Methods and Systems of Delivering Medication Via Inhalation
GB0621707D0 (en) 2006-10-31 2006-12-13 Univ London Pharmacy Formulations for delivery via pressurised metered dose inhalers
EP2091551B1 (en) 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
US8414909B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
WO2008112368A2 (en) 2007-02-08 2008-09-18 Emisphere Technologies, Inc. Phenylalkylcarboxylic acid delivery agents
US8252807B2 (en) 2007-03-02 2012-08-28 Board Of Regents, The University Of Texas System Methods of inhibiting the interaction between S100 and the receptor for advanced glycation end-products
US20080214491A1 (en) 2007-03-02 2008-09-04 Logsdon Craig D Methods of Inhibiting the Interaction Between S100 and the Receptor for Advanced Glycation End-Products
WO2008116165A2 (en) 2007-03-21 2008-09-25 Next Safety, Inc. Methods and systems of delivering medication via inhalation
US7897776B2 (en) 2007-04-23 2011-03-01 Salutria Pharmaceuticals Llc Sulfonamide containing compounds for treatment of inflammatory disorders
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
JP5460600B2 (ja) 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
EA201070479A1 (ru) 2007-10-15 2010-12-30 Сентокор Орто Байотек Инк. Человеческие антиамилоидные антитела, композиции, способы и их применение
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
AU2008323920B2 (en) 2007-11-06 2012-12-20 3M Innovative Properties Company Medicinal inhalation devices and components thereof
NZ586106A (en) 2007-12-20 2012-09-28 Astrazeneca Ab Device, typically for medicament powder, for deaggregating powder by passing air stream along flat region with recess of brick shape where eddy is generated
WO2009103067A2 (en) 2008-02-14 2009-08-20 The Children's Hospital Of Philadelphia Compositions and methods to treat asthma
WO2009131695A1 (en) 2008-04-25 2009-10-29 Nektar Therapeutics Oligomer-bis-chromonyl compound conjugates
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ589434A (en) 2008-06-03 2012-11-30 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297208A4 (en) 2008-06-03 2012-07-11 Abbott Lab DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES
US10517839B2 (en) 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
RU2559525C2 (ru) 2008-07-08 2015-08-10 Эббви Инк Белки, связывающие простагландин е2, и их применение
US20100087455A1 (en) 2008-10-06 2010-04-08 Auspex Pharmaceuticals, Inc. Substituted xanthine compounds
US20110195924A1 (en) 2008-10-08 2011-08-11 Logsdon Craig D Methods of Inhibiting the Interaction Between S100P and the Receptor for Advanced Glycation End-Products
WO2010057215A1 (en) 2008-11-17 2010-05-20 Wayne State University Engineering porous particles of water soluble therapeutics for pressurized metered-dose inhaler formulations
WO2010065882A1 (en) 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US8383778B2 (en) 2009-01-29 2013-02-26 Abbvie Inc. IL-1 binding proteins
EP2391618B1 (en) 2009-01-29 2019-04-03 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP3235509A1 (en) 2009-03-05 2017-10-25 AbbVie Inc. Il-17 binding proteins
US8470805B2 (en) 2009-04-30 2013-06-25 Kaohsiung Medical University Processes for preparing piperazinium salts of KMUP and use thereof
SG175427A1 (en) 2009-05-01 2011-12-29 Abbott Lab Dual variable domain immunoglobulins and uses thereof
PL2248517T3 (pl) 2009-05-08 2014-08-29 Pari Pharma Gmbh Stężone formulacje farmaceutyczne stabilizujące komórki tuczne
TW201109438A (en) 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
BR112012004710A2 (pt) 2009-09-01 2016-08-16 Abbott Lab imunoglobulinas de domínio variável duplo e uso das mesmas
TW201124427A (en) 2009-10-15 2011-07-16 Abbott Lab IL-1 binding proteins
PH12012500691A1 (en) 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TR201000733A2 (tr) 2010-02-02 2011-08-22 Bi̇lgi̇ç Mahmut Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
AU2015200579A1 (en) 2010-04-07 2015-02-26 Abbvie Inc. TNF-alpha binding proteins
AU2011237679B2 (en) 2010-04-07 2014-11-06 Abbvie Inc. TNF-alpha binding proteins
AU2016222339B2 (en) 2010-05-14 2017-11-23 Abbvie Inc. IL-1 binding proteins
AU2011252883B2 (en) 2010-05-14 2015-09-10 Abbvie Inc. IL-1 binding proteins
US8586044B2 (en) 2010-05-28 2013-11-19 Northwestern University Treatment of chronic pelvic pain syndrome
US9592220B2 (en) 2010-06-17 2017-03-14 Aradigm Corporation Diagnosis and treatment methods for entry of gastrointestinal contents into respiratory tract
JP5850932B2 (ja) 2010-07-21 2016-02-03 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 吸入器
MX2013002270A (es) 2010-08-26 2013-05-14 Abbvie Inc Inmonoglubinas de dominio variable doble y usos de las mismas.
SG191712A1 (en) 2010-11-02 2013-08-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
US8853365B2 (en) 2010-12-21 2014-10-07 Abbvie Inc. Dual variable domain immunnoglobulins and uses thereof
TW201307388A (zh) 2010-12-21 2013-02-16 Abbott Lab Ｉｌ－１結合蛋白
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
JP5996553B2 (ja) 2010-12-30 2016-09-21 ジブ エム．ディー． ハリシュ， 果実および／または野菜との口腔接触に起因する口腔アレルギー症状の表面適用による予防および／または処置のための調製物
GB201110058D0 (en) 2011-06-15 2011-07-27 3M Innovative Properties Co Medicinal inhalation devices, valves and components thereof
WO2013034910A1 (en) 2011-09-06 2013-03-14 Verona Pharma Plc Inhalable compositions
AR090047A1 (es) 2011-12-30 2014-10-15 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
UY34557A (es) 2011-12-30 2013-07-31 Abbvie Inc Dominio variable dual de inmunoglobulinas y sus usos
CN107929743B (zh) 2012-01-18 2023-09-01 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
GB2498746A (en) 2012-01-26 2013-07-31 Innovata Biomed Ltd Inhaler which locks when empty
NZ722952A (en) 2012-02-28 2018-12-21 Iceutica Holdings Inc Inhalable pharmaceutical compositions
US20150018396A1 (en) 2012-03-08 2015-01-15 President And Fellows Of Harvard College Prevention and treatment of respiratory infection with peroxisome proliferator activator receptor delta agonist
SG11201406142XA (en) 2012-03-27 2014-10-30 Univ Duke Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage
US10105500B2 (en) 2012-05-09 2018-10-23 Virginia Commonwealth University Dry powder inhaler (DPI) designs for producing aerosols with high fine particle fractions
MX2014013998A (es) 2012-05-25 2015-07-06 Xlear Inc Composiciones antimucosidad a base de xilitol y metodos y composiciones.
US9427534B2 (en) 2012-07-05 2016-08-30 Clement Clarke International Ltd. Drug delivery inhaler devices
TW201402608A (zh) 2012-07-12 2014-01-16 Abbvie Inc Ｉｌ－１結合蛋白質
PL2888281T3 (pl) 2012-08-21 2019-03-29 Sanofi Biotechnology Sposoby leczenia lub zapobiegania astmie przez podawanie antagonisty IL-4R
JP6499077B2 (ja) 2012-10-25 2019-04-10 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病と関連疾患の治療のための併用療法
CA2891097A1 (en) 2012-11-16 2014-05-22 Merck Sharp & Dohme Corp. Process for making agglomerates using acoustic mixing technology
WO2014115098A1 (en) 2013-01-26 2014-07-31 Mahesh Kandula Compositions and methods for the treatment of neurological diseases and inflammation
JP2016517277A (ja) 2013-03-15 2016-06-16 アッヴィ・インコーポレイテッド ＴＮＦαに対して指向された二重特異的結合タンパク質
CA2913235C (en) 2013-05-23 2021-07-13 Aztherapies, Inc. Methods for delivering cromolyn
MX367657B (es) 2013-08-23 2019-08-30 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o crónica.
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9492408B2 (en) 2013-10-24 2016-11-15 University of Pittsburgh—of the Commonwealth System of Higher Education Protection from chemical-induced acute lung injury
GB2522727B (en) 2013-11-26 2017-01-25 Purity Health Pharma Ltd Pulmonary delivery devices
EP2883564A1 (en) 2013-12-16 2015-06-17 PARI Pharma GmbH Aerosol delivery device and method of operating the aerosol delivery device
WO2015120138A2 (en) 2014-02-05 2015-08-13 Dana-Farber Cancer Institute, Inc. AGENTS THAT MODULATE RGMb-NEOGENIN-BMP SIGNALING AND METHODS OF USE THEREOF
CA2938996A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Methods for the treatment of lung diseases with mast cell stabilizers
US20150273119A1 (en) 2014-03-26 2015-10-01 Snu R&Db Foundation Formulation comprising anti-scarring agents and biocompatible polymers for medical device coating
US20150306107A1 (en) 2014-04-24 2015-10-29 Jansfat Biotechnology Co., Ltd. SAA Derivative Compound Restores eNOS And Inhibits Oxidative Stress-Induced A Diseases In Hypoxia
WO2015161510A1 (en) 2014-04-25 2015-10-29 Jansfat Biotechnology Co., Ltd. Saa derivative compound restores enos and inhibits oxidative stress-induced diseases in hypoxia
US20150337315A1 (en) 2014-05-20 2015-11-26 Michael M. Grunstein Compositions and methods targeting signaling by the g protein beta-gamma subunit for the treatment of asthma
DE102014009164A1 (de) 2014-06-03 2015-12-03 Herbalist & Doc Gesundheitsgesellschaft Mbh Silikonölhaltige nasal anzuwendende Formulierungen
CA2953214A1 (en) 2014-06-05 2015-12-10 Transgenion-International Institute For Regenerative Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
CA2953210A1 (en) 2014-06-05 2015-12-10 Transgenion-International Institute For Regenerative Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
EP3152328A2 (en) 2014-06-05 2017-04-12 Transgenion-International Institute For Regenerative Translational Medicine Gmbh Methods of diagnosing chronic obstructive pulmonary disease (copd) using novel molecular biomarkers
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
WO2016011254A1 (en) 2014-07-16 2016-01-21 Henry J. Legere Md, Pa Combinations of antihistamines and leukotriene antagonists and methods of use thereof
CN106715386B (zh) 2014-09-30 2018-09-25 株式会社Lg化学 (甲基)丙烯酸酯化合物以及包含衍生自其的重复单元的共聚物和均聚物
WO2016064908A1 (en) 2014-10-25 2016-04-28 Sumner Bluffs, Llc. Systems and methods for determining compliance and efficacy of a dosing regimen for a pharmaceutical agent
WO2017011729A1 (en) * 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
HK1258650A1 (zh) 2015-09-14 2019-11-15 Vgsk Technologies, Inc. 皮下、舌下和口服治疗用空间稳定载体、用於治疗哺乳动物的组合物和方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140024217A1 (en) * 2011-03-29 2014-01-23 Fujifilm Corporation Method for forming resist patterns and method for producing patterend substrates employing the resist patterns
US9962363B2 (en) * 2014-02-10 2018-05-08 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255394A4 (en) * 2020-12-07 2024-10-09 MannKind Corporation METHOD AND COMPOSITION FOR THE TREATMENT OF PULMONARY FIBROSIS

Also Published As

Publication number Publication date
US10265267B2 (en) 2019-04-23
US20180193259A1 (en) 2018-07-12
AU2017321495A1 (en) 2019-03-21
WO2018044942A1 (en) 2018-03-08
US20200155452A1 (en) 2020-05-21
EP3506893A1 (en) 2019-07-10
CA3035528A1 (en) 2018-03-08
EP3506893A4 (en) 2020-01-22
US20190175503A1 (en) 2019-06-13
US10463613B2 (en) 2019-11-05
JP2019528320A (ja) 2019-10-10
CN110139646A (zh) 2019-08-16

Similar Documents

Publication Publication Date Title
US10463613B2 (en) Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
US10398673B2 (en) Mast cell stabilizers treatment for systemic disorders
US10596146B2 (en) Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10391078B2 (en) Methods for the treatment of mast cell related disorders with mast cell stabilizers
US10561635B2 (en) Cromolyn compositions for treatment of pulmonary fibrosis

Legal Events

Date Code Title Description
AS Assignment

Owner name: PATARA PHARMA, LLC, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TUTUNCU, AHMET;SONI, PRAVIN;GERHART, WILLIAM;REEL/FRAME:045783/0717

Effective date: 20161205

AS Assignment

Owner name: RESPIVANT SCIENCES LTD., BERMUDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PATARA PHARMA, LLC;REEL/FRAME:047922/0902

Effective date: 20180828

AS Assignment

Owner name: RESPIVANT SCIENCES GMBH, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:RESPIVANT SCIENCES LTD.;REEL/FRAME:047945/0786

Effective date: 20181129

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STCV Information on status: appeal procedure

Free format text: NOTICE OF APPEAL FILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION